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ABSTRACT 
 
 
SMART INTERVENTIONS FOR EFFECTIVE MEDICATION ADHERENCE 
 
BY 
 
NEETU SINGH 
 
30-JUN-2016 
 
Committee Chair: Dr. Upkar Varshney 
Major Academic Unit: Computer Information Systems 
 
In this research we present a model for medication adherence from information systems and 
technologies (IS/IT) perspective. Information technology applications for healthcare have the 
potential to improve cost-effectiveness, quality and accessibility of healthcare. To date, 
measurement of patient medication adherence and use of interventions to improve adherence are 
rare in routine clinical practice. IS/IT perspective helps in leveraging the technology 
advancements to develop a health IT system for effectively measuring medication adherence and 
administering interventions. 
Majority of medication adherence studies have focused on average medication adherence. 
Average medication adherence is the ratio of the number of doses consumed and the number of 
 v 
doses prescribed. It does not matter in which order or pattern patients consume the dose. Patients 
with enormously diverse dosing behavior can achieve the same average levels of medication 
adherence. The same outcomes with different levels of adherence raise the possibility that 
patterns of adherence affect the effectiveness of medication adherence. We propose that 
medication adherence research should utilize effective medication adherence (EMA), derived by 
including both the pattern and average medication adherence for a patient. 
Using design science research (DSR) approach we have developed a model as an artifact for 
smart interventions. We have leveraged behavior change techniques (BCTs) based on the 
behavior change theories to design smart intervention. Because of the need for real time 
requirements for the system, we are also focusing on hierarchical control system theory and 
reference model architecture (RMA). The benefit of using this design is to enable an intervention 
to be administered dynamically on a need basis. A key distinction from existing systems is that 
the developed model leverages probabilistic measure instead of static schedule. We have 
evaluated and validated the model using formal proofs and by domain experts. 
The research adds to the IS knowledge base by providing the theory based smart 
interventions leveraging BCTs and RMA for improving the medication adherence. It introduces 
EMA as a measurement of medication adherence to healthcare systems. Smart interventions 
based on EMA will further lead to reducing the healthcare cost by improving prescription 
outcomes. 
Keywords: Effective medication adherence, smart intervention, context-aware reminder, 
performance evaluation, health IT artifact, information systems and technologies   
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Chapter 1. Introduction 
Information technology (IT) applications for healthcare have the potential to improve cost-
effectiveness, quality and accessibility of healthcare (Chiasson and Davidson 2004). The 
potential benefits of IT in healthcare can be realized by addressing the social issues (Braa et al. 
2007; Kaplan 2001; Miscione 2007) related to healthcare. According to the World Health 
Organization (WHO 2003), medication nonadherence poses a serious social challenge and needs 
to be addressed to improve the healthcare quality and minimize the healthcare cost. In healthcare 
literature various interventions have been designed to improve medication adherence (Choi et al. 
2008; Maulucci and Somerville 2011; McDonald et al. 2002; Schreier et al. 2013). The 
measurement of patient medication adherence and use of interventions to improve adherence are 
rare in routine clinical practice (Ho et al. 2009). A theoretical approach to study medication 
adherence improvement is largely missing in literature (Ruppar 2010). The research in this field 
needs advances, including improved design of feasible long-term interventions, objective 
adherence measures, and sufficient study power to detect improvements in patient-important 
clinical outcomes (Nieuwlaat et al. 2014). In this research we present a model based on health 
behavior change theories to study medication adherence from information systems and 
technologies (IS/IT) perspective. IS/IT perspective helps in leveraging the technology 
advancements to develop a health IT system for effectively measuring medication adherence and 
administering interventions.  
Medication adherence is “the extent to which a patient act by the prescribed interval, and a 
dose of a dosing regimen.” (Cramer et al. 2008). Adherence to prescribed medication regimens is 
critical to the quality of patient outcomes such as symptoms and other aspects of well-being, 
functioning, health status, general health perceptions, quality of life, health-related quality of life, 
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reports and ratings of healthcare. Nonadherence in patients leads to a substantial worsening of 
disease, death, and increased healthcare costs. In general, 80% medication adherence is 
considered satisfactory for chronic conditions; however, a higher level (95%) may be needed for 
acute conditions (Haynes et al. 2008; Osterberg and Blaschke 2005; WHO 2003).  
Approximately 3.2 billion annual prescriptions are dispensed in the United States alone, and 
about 50% of these prescriptions are not consumed as prescribed (Osterberg and Blaschke 2005; 
Sicre 2007). Figure 1 shows for every 100 prescriptions that physicians write, only 50% - 70% 
reach pharmacy, 48% - 66% get filled, 25% - 30% taken properly and 15% - 20% refilled as 
prescribed (NACDS 2010). 
Figure 1. Gap between a written prescription and actual medication use (NACDS 2010) 
A retrospective analysis of insurance claims confirms the earlier findings that poor 
medication adherence is a common problem across most chronic conditions (Thier et al. 2008). 
Nonadherence is not only prevalent but also has dramatic effects on individual and population-
level health. Approximately 125,000 deaths per year in the United States are associated with 
nonadherence to medication (McCarthy 1998). Although the consequences of suboptimal 
adherence to medications are quite variable, poor adherence clearly poses a threat to the health of 
the U.S. population (Peterson et al. 2003; WHO 2003) that must be addressed to reduce the gap 
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between potential and actual healthcare quality. Extensive health benefits would result from 
improving medication adherence to existing treatments than developing any new medical 
treatments (Sabate 2007).  
An economic burden of $100 to $300 billion per year came from medication nonadherence 
(NEHI 2009). Substantial evidence suggests that benefits attributable to improved self-
management of chronic diseases could result in a cost-to-savings ratio of approximately 1:10 
(Sabate 2007). As represented in Figure 2, nonadherence accounts for 10% to 25% of hospital 
and nursing home admissions. Recent research has found that medication nonadherence results 
in: 
 5.4 times increased risk of hospitalization, re-hospitalization, or premature death for patients 
with high blood pressure (Gwadry-Sridhar et al. 2009), 
 2.5 times increased risk of hospitalization for patients with diabetes (Lau and Nau 2004), and 
 More than 40 percent of nursing home admissions (Lau and Nau 2004). 
 
Figure 2. Impact of medication adherence on hospitalization risk (Sokol et al. 2005) 
Rates of adherence, which is reported as the percentage of the prescribed doses of the 
medication taken by the patient over a specified period, have not changed much in the last five 
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decades. The extent of nonadherence varies widely, and in different studies, it has been recorded 
as low as 10% and as high as 92% (Osterberg and Blaschke 2005; Sokol et al. 2005). 
Approximately half of nonadherence is intentional, while the remaining are unintentional 
because patients are either unaware that they are not taking medications as prescribed, or the 
regimen is just too complex. Adherence rates are typically higher among patients with acute 
conditions, as compared against those with chronic conditions. Studies reveal that patients with 
chronic illnesses take only approximately 50% of medications prescribed for those conditions. 
Adults aged 18–64 were almost twice as likely as adults aged 65 and over to have skipped doses, 
forget to take medicine, to have taken less medicine, and to have delayed filling a prescription to 
save money (Cohen and Villarroel 2015). 
Nonadherence is a multidimensional problem influenced by several factors including patient 
views and beliefs, illness characteristics, social contexts, access and healthcare service issues. 
The problem is likely to grow as the population ages and as patients take more medications to 
treat chronic conditions. The potential burden of medication nonadherence outcomes on 
healthcare delivery makes it a significant public health concern as evident from the World Health 
Organization and the Institute of Medicine goals to improve medication adherence (Sokol et al. 
2005; WHO 2003). 
The recognition of the importance of medication adherence has been increasing over the last 
decade. To improve health outcomes, healthcare practitioners should engage with patients and 
educate them on the importance of proper medication use (Braithwaite et al. 2013). For the 
healthcare service providers, helping patients take medication as prescribed would help in 
avoiding risks of relapses, antibiotic resistance, and preventable hospitalizations. 
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An intervention is the means of interfering with the outcome or course especially of a condition 
or process (as to prevent harm or improve functioning). In medicine, an intervention is usually 
undertaken to help treat or cure a condition. Medication nonadherence is a growing concern to 
clinicians, healthcare systems, and other stakeholders because of mounting evidence that it is 
prevalent and associated with adverse outcomes and higher costs of care (Ho et al. 2009). 
Section 1.1 Research Problem 
Medication adherence is critical to the quality of patient outcomes, but high adherence is 
difficult to achieve. Former United States Surgeon General C. Everett Koop once said, “Drugs 
do not work in patients who do not take them” (Osterberg and Blaschke 2005). This simplistic 
yet accurate statement summarizes the dilemma faced by healthcare providers and patients in the 
quest for optimum healthcare. Healthcare providers (as part of a healthcare team within the 
health system) are an integral component of the five interacting dimensions of medication 
adherence identified by the World Health Organization (2003), which include social and 
economic dimension, healthcare system dimension, condition-related dimension, therapy-related 
dimension, and patient-related dimension. The multidimensional problem of nonadherence has a 
complex environment. Identifying strategies for improving medication adherence is a 
collaborative effort of all stakeholders.  
This research examines the issue of nonadherence by focusing on (1) measurement of 
patient’s medication adherence and (2) use of mobile technologies to improve adherence among 
patients who self-administer prescribed medications in routine clinical practice. The premise for 
the focus is that concordance between the patient and provider initiates the dosing regimen. The 
dosing regimen is observable over a period of medication/therapy persistence. The current 
healthcare technologies provide sufficient tools that are leveraged without modifications to 
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observe the actual dosing of medicines by the patient. The need, therefore, is to leverage 
information systems in designing a system that can help the providers in measuring the 
adherence within the persistence period and provide the ability to administer intervention. The 
ability to measure and improve medication adherence could lead to overall improvement in the 
patient’s health outcome. 
Average medication adherence (AMA) is the predominantly used measure of medication 
adherence. AMA considers an average dosing rate and is observable after medication 
persistence. In the current system, the patient taking the medication self-reports to the provider 
towards the end of medication persistence at the time of prescription refill or if there is a concern 
from a patient with the prescribed treatment. The best the provider or patient can do is to 
schedule reminders to take medications on time (simple intervention). This research recognizes 
medication persistence as a window that is monitored to (1) detect when intervention is needed 
and (2) identify what intervention to administer.  
In the envisioned system, the rate of adherence is a probability estimate based on the 
medication behavior (pattern of medication adherence) of the patient and is termed Effective 
Medication Adherence (EMA). EMA identifies when and what intervention is administered. In 
envisioned system, intervention is not provided if the patient exhibits medication adherence. As 
interventions are not scheduled for administration at concordance but dynamically generated 
(when), and type is determined (what) based on the EMA, we deem such interventions as 
‘context-aware’ or ‘smart’ interventions. 
Section 1.2 Research Questions 
The goals of this research are to (1) analyze the patterns of adherence with prescribed self-
administered medications and its impact on effectiveness of medication adherence, (2) develop a 
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model for intervention (smart intervention) to improve effectiveness of medication adherence 
and reduce healthcare costs, and (3) provide a theoretical base to articulate, formalize, and fully 
understand the model. The research questions we will address in this study are: 
RQ1: How patterns of medication adherence impact effective medication adherence (EMA)? 
RQ2: How smart interventions improve effective medication adherence (EMA)? 
RQ3: How smart interventions reduce healthcare cost? 
Section 1.3 Research Approach  
The significant prospect in this research is the development of health information technology 
system for smart intervention to address the problem of nonadherence among patients prescribed 
self-administered medications for chronic disease. The central exercise for this research is to 
develop a model as an artifact for smart intervention based on effective medication adherence so 
as to improve simple interventions. A model is developed as an artifact to enable the 
representation, analysis, understanding, development and subsequent refinement of smart 
interventions. The implementation of artifact is done on wireless based smart medication 
management system (Varshney 2011) or smartphones. 
The Design Science Research (DSR) Process is a natural fit for developments that are 
improvements over an existing model (Vaishnavi et al. 2007). Awareness of common problem 
motivates the DSR process. Design science research initiates with a significant prospect, 
challenging problem, or creativity/conjecture for some innovativeness in the application 
environment (Hevner 2007; Hevner et al. 2004; Iivari 2007; Vaishnavi and Kuechler 2015). The 
effective solution of the problem is provided by developing a better interface (Vaishnavi et al. 
2007). The focus of design science research is to understand the phenomenon, some or all of 
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which may be created artificially instead of naturally occurring, thereby leading to artifact design 
and evaluation.  
The DSR process model developed and revised by Vaishnavi and Kuechler (2015) is shown 
in Figure 3. It also shows cognitive processes used in the DSR process. 
 
 
* Circumscription is the discovery of constraint knowledge about theories gained through detection 
and analysis of contradictions when things do not work according to theory (McCarthy 1980). 
Figure 3. Design science research process model (DSR cycle) & cognitive processes 
In the DSR process, all design begins with an awareness of the problem. In this step, the 
researcher defines the problem to be solved via the research process. Suggestions for solutions to 
the problem are drawn from the existing knowledge and theory bases for the problem area 
(Peirce 1931) or developed using an appropriate research methodology. The cognitive process of 
assimilation of knowledge is abductive at this step. Next, in the development step, the researcher 
implements an artifact according to the suggested solution. The implementation is evaluated 
according to the functional specification stated implicitly or explicitly in the suggestion step. The 
researcher may iteratively perform the suggestion, development, and evaluation steps during the 
research. The circumscription (the basis of the iteration) represents the addition of knowledge 
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from the development and evaluation steps of the process to the initial awareness of the problem, 
so that the problem can be re-examined. The cognitive process of assimilation of knowledge is 
deductive at this stage. The conclusion indicates the reflective stage where the research is 
concluded with the formulation of propositions relating to the problem domain. The steps of 
DSR process steps and output are described in Table 1 and Table 2.  
Steps Description 
Awareness of 
Problem Step  
An awareness of an interesting research problem may come from multiple 
sources including new developments in industry or a reference discipline. The 
output of this phase is a proposal, formal or informal, for a new research 
effort. 
Suggestion Step New functionality is envisioned based on a novel configuration of either 
existing or new and existing elements. 
Development Step The tentative design is further developed and implemented in this phase. The 
techniques for implementation will, of course, vary depending on the artifact 
to be created. The novelty is primarily in the design, not the construction of 
the artifact. 
Evaluation Step Once constructed, the artifact is evaluated according to implicit expectations 
or explicit criteria (Awareness of Problem phase). Deviations from 
expectations, both quantitative and qualitative, are explained, and Propositions 
are made. The deviations from the theoretical performance are iteratively 
refined by including new observations into the suggestion. 
Conclusion Step Not only are the results of the effort consolidated at this phase, but the 
knowledge gained in the effort is frequently categorized as either repeatable or 
anomalous. Future research areas are identified, and knowledge contribution 
(Gregor and Hevner 2013) is noted. 
Table 1. Design science research process steps (Vaishnavi and Kuechler 2015) 
 
Output Description 
Constructs The conceptual vocabulary of a domain 
Models Sets of Propositions or statements expressing relationships between 
constructs 
Frameworks Real or conceptual guides to serve as support or guide 
Architectures High level structures of systems 
Design Principles Core principles and concepts to guide design 
Methods Sets of steps used to perform tasks; how-to knowledge 
Instantiations Situated Implementations in certain environments that do or do not 
operationalize constructs, models, methods, and other abstract artifacts; in 
the latter case, such knowledge remains tacit. 
Design Theories A prescriptive set of statements on how to do something to achieve a 
certain objective. A theory usually includes other abstract artifacts such as 
constructs, models, frameworks, architectures, design principles, and 
methods. 
Table 2. Design science research output (Vaishnavi and Kuechler 2015) 
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In this research, the model for smart intervention is developed using the guidelines of 
Vaishnavi and Kuechler  (2015) and evaluated for effectiveness using the formal proofs and 
evaluation by domain experts (Healthcare providers and Health IT experts) (Cleven et al. 2009; 
Gregor and Hevner 2013; Parsons and Wand 2008). The DSR process steps and the 
corresponding outputs of each step are listed in Table 3 to outline the specific outputs from this 
research. 
DSR Process Steps DSR Outputs Specific Outputs 
Awareness of Problem Proposal Medication Adherence (MA) Improvement 
Suggestion Tentative Design Smart Intervention 
Development Artifact Model 
Evaluation Performance Measures Effective Medication Adherence (EMA) 
Conclusion Results Propositions 
Table 3. Specific research output at DSR process steps 
A literature review is conducted to understand the current state of the research on the topic of 
medication adherence and the various interventions that presently exist. Specifically, 
environment and the factors that affect the medication adherence are studied. Any theoretical 
basis for medication nonadherence is analyzed for gaining a better understanding of the problem 
conceptually and the limitations therein. The guiding question for the awareness of problem step 
is - If interventions to medication nonadherence can improve medication adherence, why such 
interventions are not effective?  
The understanding gained from the awareness of problem leads to the formulation of 
suggestions that could address the effectiveness of the interventions in improving medication 
adherence. The guiding question for suggestion step of the DSR process is – How can the 
effectiveness of interventions be improved? 
When a suggestion for improving the effectiveness of the intervention is identified, a model 
is developed. As existing interventions are designs, a model (sets of propositions or statements 
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expressing relationships between constructs) is an appropriate artifact to improve the design as it 
provides the lowest possible level of operative environment for the constructs. The guiding 
question for development step of the DSR process is - How closely does the new model represent 
the original model/design of the available interventions? 
The model from development step of DSR process is evaluated to examine the effectiveness 
of the improvements as envisioned in the suggestion step and according to the criteria for 
effective intervention identified in the awareness of problem step of DSR process. Propositions 
are developed about the behavior of the model. If the model does not behave as expected, 
revisions to the suggestion are made from the additional information gained in the development 
and evaluation steps and the directions suggested by deviations from expected performance. The 
development and evaluation steps are then repeated. The guiding question for evaluation step of 
the DSR process is – What are the limiting conditions for the effectiveness of interventions 
utilizing new model? 
The final step in research following the DSR process is the conclusion. In addition to the 
practical implication of this research, the theory, and knowledge gained from model development 
and evaluation can become a part of design science knowledge base thereby bridging some of the 
literature gaps that currently exist from DSR perspective. The guiding question for conclusion 
step of the DSR process is – Do the smart interventions improve effectiveness of medication 
adherence? 
Section 1.4 Research Contributions 
This research aims to contribute model for theory based smart interventions that could 
improve effective medication adherence in a group of patients who are prescribed self-
administered medication for chronic condition, thereby reducing the healthcare costs.  
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The significance of proposed research is three fold. First, it is significant to the healthcare 
system as the intervention will help in understanding the patterns of adherence and improves the 
effective medication adherence. As better health outcome is achieved, the financial burden of 
nonadherence will decrease. Second, it will provide an artifact which can be further evaluated 
using the field study. It will add value to the design science research community by providing a 
health IT domain specific artifact and by improving domain-specific information systems and 
processes. Third, it addresses the need of theoretical interventions for improving medication 
adherence. 
What is already known about the topic? 
 Medication nonadherence is a widely acknowledged and pervasive healthcare issue. 
 Medication adherence holds particular significance for individuals diagnosed with chronic 
conditions. 
 Various interventions have been designed to improve medication adherence, but few theories 
describe specifically the processes involved.  
 Despite five decades of research, current interventions do not consistently enhance 
medication adherence. 
 Current interventions focus on improving average medication adherence. The interventions 
are not generated dynamically.  
 Some of the existing medication adherence applications report the nonadherence to 
healthcare providers, but they do not facilitate the advice/scheduling from healthcare 
providers.  
 Existing technologies monitor and report nonadherence toward the end of medication 
persistence. 
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What this research adds? 
 The scope of this dissertation research is to describe the IS/IT processes involved in 
developing the health IT artifact as an intervention to improve effective medication 
adherence.  
 We address the area of medication adherence using health behavior change theory and 
reference model architecture theory. We discuss the application of health behavior change 
theory as the basis for an intervention to improve effective medication adherence.  
 We evaluate that patterns of adherence and average medication adherence are important 
predictors of medication adherence improvement. 
 Using design science research approach, we have developed model for effective medication 
adherence (MEMA), a health IT artifact as a system to administer smart intervention to 
improve effective medication adherence. Model for effective medication adherence include 
interactive presence of following components: 
1. Wireless medication box (WMB) which provides the dispensing and consumption 
information. 
2. Dynamically generated context-aware reminders using the three way interaction between 
wireless medication box (WMB), medication management application (MMA) and 
medication management server (MMS).  
3. Analysis of medication behavior that will be helpful in understanding the impact of 
nonadherence on treatment outcome. 
Section 1.5 Research Limitations 
The limitation of this dissertation lies in the fact that the health IT artifact is not generalizable 
to general healthcare area for medication adherence improvement. It is useful for chronic 
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conditions and unintentional nonadherence. More specifically, a model for effective medication 
adherence applies to unintentional nonadherence, and the intervention improves the effective 
medication adherence, i.e., the transition from Quadrant IV to Quadrant I of Figure 4. In this 
research, we are not focusing on unwilling patients. Figure 4 shows the intentional and 
unintentional nonadherence criteria. 
The current design has the limitation that patient should be willing to take medication as this 
intervention is for prescribed self-administered medications. Regarding artifact evaluation, it can 
be further extended by conducting a field study where the modeled artifact can be made 
accessible to patients and healthcare provider to use. It will help in empirical validation of the 
artifact in future research. 
 
Figure 4. Intentional and unintentional nonadherence 
(Ho et al. 2009; Lehane and McCarthy 2007) 
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Chapter 2. Awareness of Problem 
The effectiveness of treatment depends on both the efficacy of a medication and patient 
adherence to the therapeutic regimen. Patients, healthcare providers, and healthcare systems, all 
have a role in improving medication adherence. A single method cannot improve medication 
adherence. Instead, a combination of various adherence techniques should be implemented to 
improve patient’s adherence to the prescribed treatment. 
Section 2.1 Role of Patient 
Medication adherence is the extent to which patients follows the prescribed medication 
regimens (Cramer et al. 2008). Adherence is the preferred term because compliance suggests 
passivity on the part of the patient and a lack of a therapeutic alliance between patient and 
provider (Osterberg and Blaschke 2005; Steiner and Earnest 2000).  
The manner in which a patient adheres to a prescribed medication regimen influences the 
health outcomes, healthcare utilization, and healthcare costs (Chewning and Sleath 1996; 
Delgado 2000). Multiple interrelated psychosocial factors affect medication adherence. These 
factors are: psychological factors (DiIorio et al. 2009), self-efficacy (DiIorio et al. 2009; Duong 
et al. 2001), social support (Duong et al. 2001; Fongwa et al. 2008), and socioeconomic issues 
(Fongwa et al. 2008; George et al. 2006).  
Self-efficacy is a primary factor affecting whether or not a person will change a behavior and 
can affect the ability to adhere to complex medication regimens. A recent study reported that 
higher self-efficacy in taking medication was associated with higher medication adherence 
(Colbert et al. 2013). 
Accurate medication adherence and the self-efficacy are important for chronic disease 
patients. Self-reports are the most commonly used tool for measuring adherence. Empowerment 
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of an individual to self-determine benefits and risks of action or behavior are crucial to change 
adherence to medication, and the willingness and ability to do it. For chronic patients, the 
cognitive and psychological burdens of treatment can often impede the medical outcome. The 
patient may not comprehend information about treatment if the amount of information becomes 
overwhelming. The patient may become unwilling to ask for help, and can undermine the 
importance of medication for the treatment.  
Nonadherence to medications can be intentional or unintentional. Intentional nonadherence is 
an active process whereby the patient chooses to deviate from the treatment regimen. There may 
be a rational decision process in which the individual weighs the risk and benefits of treatment 
against any adverse effects. Unintentional nonadherence is a passive process in which the patient 
may be careless or forgetful about adhering to the treatment regimen (Ho et al. 2009; Lehane and 
McCarthy 2007). Unintentional adherence is also referred to by Vrijens et al. (2008) as the 
execution of the prescribed regimen, or how well patients adhere to the dosing regimen. There 
are six general patterns of execution:  
(1) Close to perfect adherence; 
(2) Take nearly all doses with some timing irregularity; 
(3) Miss an occasional single day’s dose, and some timing inconsistencies; 
(4) Take drug holidays 3 to 4 times per year; 
(5) Take drug holidays monthly or more often and have frequent omissions; and 
(6) Take few or no doses. 
Most deviations in medication taking are due to omissions of doses or delays in taking doses. 
Also, it is common for patients to improve their medication-taking behavior shortly before and 
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after an appointment with a healthcare provider called “white coat adherence” (Osterberg and 
Blaschke 2005). 
Estimates of unintentional nonadherence vary considerably and range from 20% to over 50% 
(Ho et al. 2009; Lehane and McCarthy 2007). Forgetting to take medication (62%) was the most 
commonly reported behavior followed by running out of medications (37%) and being careless 
at times about taking the medication (23%) (Gadkari and McHorney 2012). Timely intervention 
can influence nonadherence of prescribed self-administered medications. The reasons for poor 
medication adherence are often multifactorial, and encompasses a wide range of behaviors. The 
consequence is an underuse or overuse of prescribed medications. 
Section 2.2 Role of Prescribers 
Healthcare providers play a unique and important role in assisting patients to carry out healthy 
behaviors (Atreja et al. 2005) and a patient’s beliefs about the benefits and risks of medicines 
influence whether or not they take prescribed medication (Wroth and Pathman 2006). The patient 
relationship with the healthcare provider influences the acquisition of knowledge and the belief 
of the importance of adherence (Phatak and Thomas 2006; Pratt et al. 2001). Collaborative care 
involving a working relationship between physicians and pharmacists has been shown to 
improve patient care and reduce medication errors (Kuo et al. 2004). Collaborative care is 
beneficial in addressing the psychosocial factors that can affect medication adherence. 
Another factor is patient and provider concordance - the extent to which patients and their 
providers agree on whether, when, and how patient takes medication. Hence, adherence requires 
the patient to believe there is a benefit to the prescribed medicine and agree with instructions on 
how to take it. Importantly, there cannot be barriers, such as cost, which will prevent medication 
access. The prescriber’s role is to gain trust from the patient, understand the patient’s belief 
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system, find a way to treat within this belief system, interactively obtain agreement from the 
patient on when and how to take prescribed medication, and discuss cost issues to ensure that 
patient adheres to the prescription. Building trust and developing skills for successful provider 
and patient communications demand time, effort, knowledge, and practice. 
In addition to prescribers, the office staff has a role in boosting patient adherence to 
medication. Wroth and Pathman (2006) evaluated correlates of medication adherence in a rural 
setting and found that when patients felt welcomed and comfortable by the staff, they were more 
likely to fill their prescriptions. 
Section 2.3 Role of Interventions 
Intervention is a treatment, procedure or program of healthcare that has the potential to 
change the course of a healthcare condition.  Interventions are classified as informational or 
behavioral. In general, interventions for improving medication adherence include reminders, 
family support, educational interventions and motivational support from healthcare providers 
among others (Friedman et al. 1996; McDonald et al. 2002). Health IT interventions implement 
some of these (Moore and Benbasat 1991).  
There have been major advances in design, implementation, and evaluations of systems for 
medication adherence. With increasing deployment of mobile and wireless technologies, 
including sensors, RFID, personal area networks, wireless LANs, and cellular networks, some of 
these interventions can be implemented on smartphone and smart medication systems (McCall et 
al. 2010; Varshney 2009). More specifically, enhancing standard care with reminders, disease 
monitoring and management, and education through applications on a smartphone can help 
improve health outcomes. These care processes have implications for both patients and providers 
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(Krishna et al. 2009). Also, a wireless-based smart medication system (SMMS)  can support 
(Varshney 2011; Varshney 2013) 
(a) Communication with patients,  
(b) Monitoring of medication consumption,  
(c) Context-sensitive reminders to patients, and  
(d) Multiple interventions for medication adherence.  
Some of the systems use wearable devices and sensors for medication adherence (Choi et al. 
2008; Choi et al. 2013; DiCarlo et al. 2012; Holmes et al. 2014). Lundell et al.  (2007) captured 
medication adherence by counting medication taking events that occurred within 90 minutes 
before and 90 minutes after the scheduled time. Electronic pill box has been developed and used 
for continuous monitoring of medication adherence (Hayes et al. 2006). In another study, an 
automated medication adherence tool is developed for imparting medication taking directions to 
patients (Maulucci and Somerville 2011).  
However, existing technologies for monitoring and improving drug adherence are either 
costly or too complicated for general patients to use. The current methods of improving 
medication adherence for chronic health problems are labor-intensive, and not predictably 
effective (Ingersoll and Cohen 2008; Lundell et al. 2007; Maulucci and Somerville 2011; McCall 
et al. 2010; Moore et al. 2011; Schreier et al. 2013; Tang et al. 2011). These methods of 
intervention do not realize the full benefits of treatment. 
Several interventions have been tried to improve the average medication adherence (Choi et 
al. 2008; Hayes et al. 2006; Ingersoll and Cohen 2008; Lundell et al. 2007; Maulucci and 
Somerville 2011; McCall et al. 2010; McDonald et al. 2002; Moore et al. 2011). Some 
interventions are implemented on smartphone (Krishna et al. 2009; Varshney 2009) and 
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medication systems (Choi et al. 2013; DiCarlo et al. 2012; Hayes et al. 2006; Holmes et al. 2014; 
McCall et al. 2010; Moore et al. 2011; Schreier et al. 2013; Tang et al. 2011; Varshney 2011). 
Most systems rely on simple alarms and do not address other determinants of health-related 
behavior (Hayes et al. 2006; Schreier et al. 2013). Although quite diverse, these systems support 
communications with the patient, medication monitoring, and interventions to improve the 
average medication adherence. 
Haynes (1976) randomly allocated, through the minimization method, 38 patients who were 
both hypertensive and nonadherent (less than 80% of prescribed pills) at the end of a six-month 
trial to an intensive adherence intervention or control. The intervention included care provided at 
the work site, special pill containers, counseling, reminders, self-monitoring of adherence and 
blood pressure, support groups, feedback and reinforcement for adequate adherence and blood 
pressure-lowering, all administered with bi-weekly contacts by a lay program coordinator who 
was supported by study funds. At six months’ follow-up, there was a significantly higher 
adherence in the intervention group.  
Most patients do not follow self-administered medical treatments as prescribed and 
interventions to help them follow treatments are marginally effective at best, especially for long-
term medical regimens. Strategies that appear to have some effect for long-term regimens 
involve combinations of counseling, reminders, self-monitoring, feedback, family therapy, 
psychological therapy, manual telephone follow-up, and supportive care. For short-term 
treatments, simpler means, including counseling, written information about the importance of 
taking all doses, and personal phone calls can achieve high adherence. 
Coomes et al. (2012) has developed a conceptual framework for using short message service 
(SMS) based intervention to improve healthcare quality and clinical outcomes for people living 
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with HIV (PLWH). They have posited that SMS-based intervention which are more personalized 
as well as consider mutually reinforcing behaviors and factors offer a unique opportunity to 
enhance treatment and prevention for PLWH (Coomes et al. 2012). Rosen et al. (2015) 
conducted a qualitative study to adapt and develop an mHealth app for HIV patients to improve 
medication adherence. The results of this study indicate that a balance of provided and requested 
information is important to maintain interest and support adherence (Rosen et al. 2015). These 
two studies provide an insight that while developing intervention, user interface and reaction to 
visual content of app is essential to adaptation and design of intervention. 
Other studies have similarly concluded that behavioral interventions like reminders are 
important in improving the medication adherence. The method of administration of reminders as 
intervention mechanism to enforce adherence is also an important factor in influencing the 
patients (Rosen et al. 2015). 
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Chapter 3. Suggestion 
Section 3.1 Evaluating adherence  
Concordance is the agreement between the provider and the patient; patient/provider 
concordance is the extent to which patients and their providers agree on whether, when, and how 
to take medication (Zulman et al. 2010). The providers uniformly underestimate the problem of 
nonadherence. If it is not suspected, it cannot be corrected. Measuring adherence can lead to 
better patient compliance. Adherence is the extent to which a patient’s behavior (regarding 
taking medication, following a diet, modifying habits, or attending clinics) coincides with 
medical or health advice (Cramer et al. 2008). Persistence is the duration of time from initiation 
to discontinuation of therapy. Continuing to take any amount of the medication is consistent with 
the definition of persistence (Cramer et al. 2008). 
 
Figure 5: Adherence versus persistence (Cramer et al. 2008) 
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Adherence, as represented in Figure 5 is a measure of the percentage of doses taken as 
prescribed over the number of day medication is taken without exceeding the permissible gaps. 
For example, if a person is prescribed an antibiotic with a dosage of one tablet three times a day 
for a week, but only takes two tablets a day for four days, adherence is 38% (8/21). 
We value adherence because studies have established that being compliant delivers the most 
effective therapeutic benefits of the prescribed medication. The stated method of measuring 
adherence gives us an average rate of taking medications and thus could model the therapeutic 
benefits arising from consuming average doses. The drawback here is it does not predict or tell 
us the effectiveness of such adherence on the derived therapeutic benefits. In an ideal world, 
everybody is assumed compliant, and the adherence is 100% and so would the effectiveness of 
adherence with 100% therapeutic benefits derived. In practical scenarios, the average dose may 
not be an effective dose. 
In pharmacology, an effective dose (ED) is the dose or amount of drug that produces a 
therapeutic response or desired effect in some fraction of the subjects taking it. Drugs are 
seldom administered in a single dose to produce the desired effect. Drugs are frequently 
administered in successive doses to bring about lasting and effectual results. Thus, to avoid the 
toxic concentrations of a drug as well as to maintain its therapeutically effective concentration 
within the plasma, one must properly contrive a multiple dosing regimen.  
Multiple Dosing Regimen We consider multiple dosing regimen with the context of 
adherence within a persistence to assess the effectiveness of each dose in producing the desired 
therapeutic output. 
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Figure 6. Repetitive dosing with adherence versus persistence 
In Figure 6, we represent a drug administered on a multiple dosing regimen; each successive 
dosage(s) administers before the preceding doses eliminate. Accumulation of the drug routinely 
occurs within the body yielding a higher plasma drug concentration. The accumulation 
phenomenon, however, does not cause the plasma concentration to rise indefinitely. Figure 7 
shows the plasma concentration plateaus where the same maximum (Cmax) and minimum (Cmin) 
concentrations are repeatedly reproduced (Lins et al. 2003). In designing a dosing regimen then, 
one's objectives would be to keep the drug concentration above the minimum effective 
concentration (MEC) and below the minimum toxic concentration (MTC). 
 
Figure 7. Plasma concentration plateaus overdosing intervals (Lins et al. 2003) 
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3.1.1 Dose Persistence 
One cannot overstate the importance of determining the therapeutic range of a drug. The 
range between the minimum effective dose (MED) and the maximum tolerated dose (MTD) 
defines the therapeutic range. The MED is the lowest dose level of a pharmaceutical product that 
provides a clinically significant response in average efficacy, which is also statistically 
significantly superior to the response provided by the placebo (Jen-pei 2010). Similarly, the 
MTD is the highest possible but still tolerable dose level on a pre-specified clinical limiting 
toxicity (Jen-pei 2010). In general, these limits refer to the average patient population. For 
instances in which there is a large discrepancy between the MED and MTD, it is stated that the 
drug has a large therapeutic window. Conversely, if the range is relatively small, or if the MTD 
is less than the MED, then the pharmaceutical product will have little to no practical value (Jen-
pei 2010). 
Figure 8 shows the persistence of the medicine over a dosing interval in the dosing regimen. 
Over a period, the effects of the medicine wear off. Dosing regimen specifies the interval to be 
duration from intake when the concentration of the drug falls below the therapeutic range. 
 
Figure 8. Dose persistence within the medication /therapy persistence 
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3.1.2 Nonadherence 
Medication adherence helps in maintaining the effective level of drug in the body. The effects 
of the medication wear off due to consumption of the drug in the body. After a period, the 
clinical effects of the medicine become ineffective and need replenishment, i.e., taking the next 
dose of the medicine. This implies that three types of dosing event (DE) is captured for 
medication adherence:  
 Consuming the medicine before the recommended interval i.e. before the time,  
 Consuming the medicine after the recommended interval i.e. after the time, and  
 Consuming the medicine at the recommended interval i.e. on time.  
Consuming the medicine before the recommended interval leads to exceeding the minimum 
tolerated dose (MTD). If the minimum time (TMIN) between two doses is not medically safe, then 
it will lead to undesirable dose event (UDE). On the other hand, consuming the medicine after 
the recommended interval exposes patient to below the minimum effective dose (MED) interval.  
 
Figure 9. Nonadherence dose persistence within the medication /therapy persistence 
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If the maximum time (TMAX) between two doses is not medically effective, then it will lead 
to dose not effective (DNE). Figure 9 shows that consuming the medicine at the recommended 
interval is the Prescribed Effective Dose (PED) event and is ideal. If any of the three events do 
not register for the prescribed interval, it will imply a skipped or a missed dose. 
3.1.3 Patterns of Adherence 
A pattern can be generated from such consumption events indicating the deviation or 
conformation to the prescribed dosing regimen and becomes the pattern of medication 
adherence. The pattern of medication adherence generates from the events associated with the 
intake of medication by the patient. Undesirable dose event (UDE) results in a higher 
concentration of medicine than the prescribed and thus deemed unsafe level in the body 
temporarily (from the time of consumption until the next scheduled time) and may require 
immediate intervention by the healthcare provider/physician.  
For the purpose of this research, UDE is reported to the healthcare provider and intervention 
is not provided. This research focuses upon dose not effective (DNE) because our emphasis is on 
the effectiveness of the adherence. Analyzing the patterns of medication adherence along with 
the average medication adherence results in a new variable termed effective medication 
adherence (EMA). EMA tracks the actual adherence to the prescribed regimen of medicine 
intake and the deviations therein considering the periods of the ineffectiveness of the medication 
dose. Figure 10 shows the different patterns of adherence to a medication therapy/persistence. 
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Figure 10. A simple pattern of adherence within the medication /therapy persistence 
Figure 11 shows the pattern of the dose persistence/dose not effective based on a skipped 
dose. The sequence in which the dose not effective intervals occur has a bearing on the 
persistence outcome. A dose not effective interval occurring earlier in medication persistence 
may have an effect quite different than the dose not effective interval towards the end of the 
medication persistence. The effectiveness of adherence would be different in both cases on the 
therapeutic outcome and thus different EMA values. Figure 12 shows the patterns can vary if we 
consider the possibility that the patient can take multiple doses or can take the dose any time 
before or after the prescribed interval between the doses, or totally skip the dose. The patterns of 
adherence affect the therapeutic effectiveness of the prescription. 
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Figure 11. Effect of patterns of adherence due to skip dose on dose persistence 
 
 
Figure 12. Various patterns of adherence due to skip dose 
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Section 3.2 Theoretical Background 
Medication adherence is a very complex multi-faceted challenge. As an enabler, Information 
Technology has a major role to play. There is a need to study medication adherence 
interventions, and theoretical models will be needed to help such study. In this research, we 
present a model to study medication adherence from IS/IT perspective, more specifically health 
IT enabled interventions.  
3.2.1 Factors 
There are several factors that can affect the medication behavior of the patient, some within 
the control and some outside the control of the patient. The effort to identify the reasons leads to 
five interacting dimensions of the medication behavior. Figure 13 shows the details of following 
five interacting dimensions of medication behavior – (1) Social and Economic Dimension, (2) 
Healthcare System Dimension, (3) Condition-Related Dimension, (4) Therapy-Related 
Dimension, and (5) Patient-Related Dimension (WHO 2003). In Appendix A3.1, different 
factors affecting medication adherence in each interacting dimension are reported (Meducation 
2006). 
 
Figure 13. The five interacting dimensions of medication behavior (WHO 2003) 
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As behavior contributes to the cause of much current mortality and morbidity (Michie and 
Johnston 2012), interventions to change medication behavior are essential in prevention. 
Behavior change interventions are usually complex, comprising many interacting components 
(Craig et al. 2008). 
3.2.2 Efficacy 
Theories summarize the state of cumulative knowledge. They specify key constructs and 
relationships and the underlying scientific explanations of the processes of change and link 
behavior change to constructs in a systematic way. They describe how, when and why change 
occurs. They allow investigators to understand why and how interventions succeed or fail. 
Rigorous testing of theoretical principles forms a basis for future interventions. Thus, theories 
are fundamental in designing behavior change interventions.  
Investigation of theory to support the problem domain is a central exercise in design science 
research. Key frameworks for designing and evaluating behavior change interventions (Collins et 
al. 2011; Craig et al. 2008) emphasize the importance of using theory to inform intervention 
design as well as specifying interventions using component behavior change techniques(BCTs). 
Behavior may refer to simple, specific actions, for example, swallowing a pill; about health, it is 
used to refer to a more complex sequence of actions. Behavior change techniques (BCTs) are 
observable and replicable components of behavior change interventions. They are the smallest 
component compatible with retaining the proposed mechanisms of change, and can be used alone 
or in combination with other BCTs (Easthall et al. 2013; Michie and Johnston 2012). Precise 
specification of BCTs may also enhance the intervention.  
Dombrowski et al. (2012) found using a BCT coding scheme that instruction, self-monitoring, 
and practice were effective techniques. Taylor et al. (2012) also found that the extent to which 
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interventions were explicitly based on theory predicted their effectiveness; a finding consistent 
with a similar analysis of collaborative interventions (Webb et al. 2010).  
The existing electronic reminder systems have been available for decades, yet there is very 
small improvement in the medication adherence behavior. Most of these systems rely on simple 
alarms and do not consider another determinant of health-related behavior. Besides the 
technology enablement, it is important to consider the personal traits of the patient entrusted with 
the prescribed self-administered medication regimen.  
For both scientific and practical reasons, it is essential that behavior change interventions 
develop a sound scientific basis. In practice, the science will inform the technology (i.e. the 
techniques and methods) required to deliver effective, replicable interventions with guidance on 
their delivery to ensure use of effective interventions. A science of behavior change needs both 
good theory and reliable technology. 
In this research, we develop a model to improve medication adherence from information 
systems and health IT perspective. Health IT enabled intervention is based on the notion of 
collaborative care as it leverages the patient-provider relationship and can help those who are 
willing to be helped. When a prescribed medication is self-administered, the choice rests with the 
patients and their motivation to take the medicine. An intervention is a mechanism to try and 
modify the behavior of the patient, in the best interests of the patient, when the concordance 
between patient and the provider breaks.  
This research examines the problem with the lens of health behavior change theories to 
predict “when” and “what” intervention is required to improve the medication adherence 
behavior of patients, thereby making the interventions “smart interventions.” Appendix A3.2 
discusses different health behavior change theories as adapted from Revere and Dunbar (2001)  
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For the purpose of this research, we are interested in a theory that can support a health IT 
artifact for affecting a behavior change. The simplest of BCTs that finds prevalence in system 
design are reminders, a component of both Health Belief Model and Stages-of-Change Model. 
We also identify effective medication adherence ‘EMA’ as a ‘Goal’ for the patient. Stages-of-
Change Model and Theory of Planned Behavior and Theory of Reasoned Action support setting 
goals and steering of the patient towards the goal. As the theories listed in Appendix A3.2 
support BCTs, we utilize the BCTs to leverage in the theory based model for effective 
medication adherence. We focus on when and what reminder (Cues to action/maintenance) to 
administer to the patient as smart intervention for improving medication adherence. 
 
Figure 14. Generalized model based on the BCTs affecting medication behavior 
Figure 14 shows a generalized theoretical model supporting the health IT system. The most 
prevalent Behavior Change Techniques leveraged in the development of the health IT system 
model are Action planning, Prompt/cues, Self-monitoring, and Feedback on behavior. These four 
techniques are based on the health behavior change theories of Stages-of-Change Model, Health 
Belief Model and Theory of Planned Behavior/Theory of Reasoned Action and specifically are 
focused on behavior changes tied to Goals and Reminders (Morrissey et al. 2015). 
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Action Planning: Prompt, detailed planning of performance of the behavior (must include at 
least one of context, frequency, duration, and intensity); context may be environmental or 
internal. An example is setting a reminder to take medication at a specific time every day  
Prompt/cues: Introduce or define environmental or social stimulus for the purpose of 
prompting or cueing the behavior; the prompt or cue would normally occur at the time or place 
of performance. A reminder alarm ringing to prompt the user to take medication is a prompt/cue 
BCT. 
Self-monitoring: Establish a method for the person to monitor and record their behavior(s) 
as part of a behavior change strategy. A dialog box that allows users to record whether they took 
or skipped their medication is a self-monitoring BCT. 
Feedback on behavior: Monitor and provide informative or evaluative feedback on the 
performance of the behavior. An example is a log or graph that displays the user’s adherence 
levels. 
As shown in the generalized model based on the BCTs affecting Medication Behavior, we 
see that patient’s medication behavior is a dynamic state that keeps changing, from the 
interventions provided by the system, and continuously feeds to the knowledge base of 
interacting dimensions of medication behavior. These medication behaviors are examined using 
the health behavior change theories. Such examinations can lead to an expansion of the existing 
theories or to postulate new theories for explaining a new or changed behavior encountered, and 
subsequently to identify new BCTs. 
3.2.3 Realization 
A key requirement for the envisioned model/health IT system is the ability to be real-time 
and dynamic i.e. administer the intervention when needed. The design of such model, or system 
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requires a feedback mechanism and ability to exert control as close to the source as possible. We 
examine the design from the theoretical perspective of control theories that provide a basis for 
real time control systems (Albus and Barbera 2005; Albus and Rippey 1994; Carver and Scheier 
1982). Control theory is an interdisciplinary branch of engineering and mathematics that deals 
with the behavior of dynamic systems with inputs, and how feedback modified their behavior. 
The objective of control theory is to control a system, so its output follows the desired control 
signal, called the reference, which may be a fixed or changing value. A controller monitors the 
output and compares it with the reference. The difference between actual and desired output, 
called the error signal, is applied as feedback to the input of the system, to bring the actual output 
closer to the reference. Mapping this to the problem of medication adherence, we model the 
control system to have the ability to capture the dosing event. The controller compares the dose 
event to the reference prescribed dose event. If the dose is not effective or the dose is 
undesirable, a feedback is generated. The feedback is the probable value of effective medication 
adherence at next prescribed dosing event. The probable value depends on the past pattern of 
medication behavior of the individual. Based on the value of feedback generated, it can be 
decided to administer intervention.  
To develop a system that can adapt to the medication behavior exhibited in real-time also 
leads us to examine the cognitive foundations for system design. A cognitive architecture is the 
organizational structure of functional processes and knowledge representations that enable the 
modeling of cognitive phenomena. The fundamental cognitive system is composed of a behavior 
generation engine driven by a model updated by a perceptual system and governed by a value 
system as shown in Appendix A3.3a. 
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Controllability and observability are main issues in the analysis of a system before deciding 
the best control strategy to be applied. Controllability is related to the possibility of forcing the 
system into a particular state by using an appropriate control signal. Observability is measuring 
the state of a system. There are several control techniques as represented in Appendix A3.3b 
which are applicable to model and strategy chosen. 
Hierarchical Control System is close to our problem domain based on the multidimensional 
nature of the problem that involves one or more than one feedback influencing the goal or 
behavior. In a hierarchical control system, intelligent control can be built as units of the control 
system without having to change the design explicitly. 
We leverage the existing hierarchical control system Reference Model Architecture (RMA) 
theory for Real time Control Systems for its extensible nature (Albus 1993; Albus and Rippey 
1994). At its core, the RMA can be mapped directly to the controlled process or real world, 
avoiding the need for a mathematical abstraction, and in which time-constrained reactive 
planning is implemented. RMA is cognitive theory based architecture designed to enable any 
level of intelligent behavior.  
RMA consists of a multi-layered multi-resolution hierarchy of computational agents each 
containing elements of sensory processing (SP), world modeling (WM), value judgment (VJ), 
behavior generation (BG), and a knowledge database (KD). At the lower levels, these agents 
generate goal-seeking reactive behavior. At higher levels, they enable decision making, planning, 
and deliberative behavior. RCS functional modules may add, subtract, multiply, differentiate, 
integrate, compute correlation functions, recognize patterns, generate names or addresses of 
symbolic representations, or perform planning functions at a hierarchy of levels. In its most 
complete theoretical form, the RCS reference model architecture provides a framework for 
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integrating concepts from artificial intelligence, machine vision, robotics, computer science, 
control theory, operations research, game theory, signal processing, filtering, and 
communications theory. 
For the purpose of developing a system for smart intervention, we are considering a single 
node that is assigned the task to decide if there is a need for intervention, and when and what 
type of reminder to administer. A single RMA node can be used to model this requirement. 
Figure 15 shows a node of RMA (Albus 1993; Albus and Rippey 1994). Each node has ability 
for:  
 Behavior generation (BG) - BG modules contain job assignment, planning, and control 
algorithms. 
 Sensory perception (SP) - SP modules process data from sensors. It contains filtering, 
masking, differencing, correlation, matching, and recursive estimation algorithms, as well as 
feature detection and pattern recognition algorithms. 
 Value judgment (VJ) - VJ modules contain algorithms for computing cost, risk, and benefit, 
for evaluating states and situations, for estimating the reliability of state estimations, and for 
assigning cost-benefit values to objects and events. VJ modules may compute statistics on 
information about the world based on the correlation and variance between observations and 
predictions. 
 World Model (WM) - The WM modules models the state space of the problem domain. They 
contain information storage and retrieval mechanisms, as well as algorithms for transforming 
information from one coordinate system to another. WM modules use dynamic models to 
generate expectations and predict the results of current and future actions. WM modules may 
contain recursive estimation algorithms and processes that compute lists of attributes from 
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images, graphics engines that generate images from symbolic lists, and recognition and 
detection algorithms that perform pattern matching operations necessary to verify the 
identification of features, surfaces, objects, and groups. The WM module maintains a 
knowledge database (KD), acts as a question answering system and uses information on from 
the KD to predict or simulate the future. 
 
Figure 15. Node of reference model architecture (Albus 1993; Albus and Rippey 1994) 
The operation of the Node of RMA is a set of steps defined by a planning period or an 
execution clock cycle: 
While the planning period is open 
{ 
BG planner hypothesizes a tentative plan; 
WM predicts the probable result of the tentative plan; 
VJ evaluates the probable result value; 
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BG planner checks to see if the probable result value is greater than the previous probable result 
value of the plan already in the current best plan buffer, 
{ 
if it is,  
then the tentative plan replaces the current plan in the current best plan buffer; 
else continue; 
} 
}; 
At the top, the highest level task is defined by the highest level (i.e., mission) goal. At each 
successive level in the hierarchy, commanded tasks from above are decomposed into subtasks 
and sent to subordinates below. Finally, at the bottom, subcommand outputs are sent to actuators 
to generate forces and movements. Also at the bottom, sensors transform energy into signals that 
provide sensory input. 
Figure 16 shows the dosing event (DE) being evaluated by a node in RMA model to plan and 
decide upon intervention based on prescribed dosing regimen (PR), dose not effective (DNE) and 
undesirable dose event (UDE). The sensory perception (SP) module registers an actual dose 
event (DE) from the patient. The value judgment (VJ) module evaluates the time of the dosing 
event by comparing it with the prescribed dosing regimen (PR) and identifying the dose not 
effective (DNE) or undesirable dose event (UDE). It then evaluates the value of effective 
medication adherence (EMA) for the next prescribed dose event based on a plan from the world 
model (WM). The value judgement (VJ) module compares the predicted the value of EMA to the 
prescribed value of EMA and takes decision to administer intervention (INTVN) based on 
applicable BCT from world model. 
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DE* - Dose Event, DNE* - Dose Not Effective, UDE* - Undesirable Dose Event, EMA* - Effective 
Medication Adherence, INTVN* - Intervention, MB* - Medication Behavior, PR* - Prescribed 
Dosing Regimen, BCT* - Behavior Control Techniques 
Figure 16. MEMA implementation of RMA node for smart intervention 
The current set of envisioned functionality is to provide a reminder (BCT) to the patients. 
The world model is enriched by knowledge module and inputs from other sensors, and the 
capability exists for enhancements in future. The usefulness of the node based on RMA model 
would be more suited is an enriched use case scenario. 
Section 3.3 Enabling Technologies 
The current technologies are promising in the terms of advancements they bring. The sensor 
technologies for clinical use are advancing rapidly, shrinking in size and becoming personal and 
prevalent. The rising cost of healthcare is forcing people to make a conscious choice to stay fit 
and healthy. The healthcare providers are enabled with collaborative technologies and are 
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becoming more capable of delivering personalized clinical treatments that are self-managed by 
the patients. The shift towards self-management is to reduce costs. The mechanisms to monitor 
the drug usage in the patients has progressed. Smart medication dispenser that can dispense 
doses as necessary (Wireless Medication Box) are available for use.  
Unfortunately, the same is not true with the application that supports medication adherence. 
We examine some of the applications that allow monitoring of the drug use and find at this time, 
only simple applications that measure average medication adherence are available and provide 
scheduled reminders. There is an opportunity for much more sophisticated and personalized 
mobile applications. Table 4 discusses current top six mobile applications used on Android/IOS 
platforms for medication adherence. Analysis of these applications shows that all these 
medication adherence applications use reminder and does not focus on goal behavior change 
technique.  
As we can see from Table 4, most of the existing medication adherence applications seem to 
be reminder applications that rely on the schedule generated in advance based on the prescribed 
dosing regimen. The dynamic scheduling (where a reminder is scheduled if there is a need) of 
intervention is missing in the existing applications. In the view of this limitation of existing apps, 
we proposed the model for effective medication adherence. The uniqueness of model for 
effective medication adherence is that it does not create a schedule for intervention. It uses 
dynamic scheduling. 
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Application 
Name 
Compatibility 
& Cost 
Features Limitations 
Medisafe Meds 
& Pill Reminder
 
Android/IOS 
Free 
• Synchronizes information to a 
“family pillbox”. 
• Allows helping family members 
with their pills.  
• Shares information with 
caretakers who can be notified if 
the patient has not checked into the 
app. 
• Provides a list of medications that 
are "due today" and check them off 
as you go. 
• Sync reminders with android wear 
a smart watch. Shake your wrist to 
mark that you took the medication. 
• May fail to consider 
lifestyle factors. 
• Users generally enter 
their own information. 
This can be barrier 
among those already 
unlikely to follow a 
schedule. 
• No context-aware 
reminders. 
• Med-Friend feature 
does not work some 
times correctly. 
MyMedSchedule
 
Android/IOS 
Free 
• Allows creating and saving easy-
to-understand medication 
schedules. 
• Shows the times of consumption 
of medications or supplements, 
how much to take, and the purpose.  
• Can set up text and email 
reminders.  
• Provides information to 
specialists about the medications 
you are taking and you can access  
• Provider data input capable 
• Does not track missed 
and taken doses 
• No persistent 
reminders 
• No context-aware 
reminders 
MyMeds  
 
Android/IOS 
Free 
• Tracks the missed doses and 
export that data to health providers 
for review. 
• When the patient properly uses 
the app, this feature can provide 
information to help healthcare 
providers assess medication 
adherence. 
• No persistent 
reminders 
• No context-aware 
reminders 
• Not capable of 
provider data input 
RxRemindMe
 
IOS 
Free 
• Tracks missed doses and export 
that data to health providers for 
review. 
• When the patient properly uses 
the app, this feature can provide 
information to help healthcare 
providers assess medication 
adherence. 
• No persistent 
reminders 
• No context-aware 
reminders 
• Cloud data storage is 
not available 
• Not capable of 
provider data input 
Med Helper
 
Android 
Free 
• Keeps track of prescriptions - 
Alarms reminds when medication 
needs to be taken when doctor’s 
appointments are scheduled and 
when medicines are running low or 
are about to expire.  
• Also tracks vital signs and PRN / 
take-as-needed medication. 
• Can log and export or print 
detailed reports for doctor, nurse or 
caregiver. 
• Does not track missed 
and taken doses 
• No persistent 
reminders 
• No context-aware 
reminders 
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Dosecast
 
Android/IOS 
Free 
• Reliable notifications: Nags you 
until you take the medicine 
• Flexible scheduling: helps you 
take doses on a 
daily/weekly/monthly schedule, 
every X day/weeks, only on certain 
days of the week, or even after a 
pre-set number of hours or days 
since the last dose. 
• Customizable dose amounts and 
instructions 
• Postpone-able reminders 
• Smart silencing 
• Private and secure: Medicine 
information is encrypted 
• Does not keep track of 
daylight savings time 
changes. 
• No context-aware 
reminders 
• Not reliable tracking 
of actual dose 
consumption as not 
connected to a smart 
pill-box 
Table 4. Current mobile applications for medication adherence 
 
3.3.1 Medication Event Monitoring System (MEMS) 
Electronic Monitoring (EM) units vary in design from standard pill containers with a 
microprocessor chip embedded in the cap to medication boxes with compartments for individual 
doses to metered-dose inhaler canisters that release puffs of medication. Most of the EM devices 
monitor medication dosing using special containers that store dosing information on a 
microprocessor inside the unit until the data downloads into the specialized software. Patients are 
shown how to use the devices and instructed not to open the unit except when medication is 
needed for dosing.  
On return to the clinic, the unit is inserted into a communicator apparatus that reads the 
electronic information and transmits it to the computer. Medication event monitoring systems are 
progressively advancing to include wireless communication facilitating the transmission of the 
information in real time. Real-time observability at source i.e. when the patient takes the 
medication is a key requirement for the design of health IT system based on Effective 
Medication Adherence. 
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3.3.2 Smart Medication Management System (SMMS) 
Smart medication management is performed by systems that can detect, process, and use 
context-awareness in creating suitable actions including reminders to patients (Varshney 2013). 
Such systems can compensate for the deficit of cognitive abilities of the elderly. Wearable, 
portable or environmental technologies capture the vital signs, health parameters, and system 
generates current context of the patient (Varshney 2011). The healthcare providers collaborate 
with one another and decision making system, which then interacts with medication management 
system for generating context-aware reminders/alerts for higher adherence. 
The system also provides context-sensitive information to assist the cognitive process 
involved in interacting with the system, obtaining and ingesting the medication(s). For example, 
the patient may need help in remembering what medications to take, what dose, when and how. 
In cases of missed or delayed doses, the system processes on its own or in some cases with the 
help of a healthcare provider. The resulting actions could be to either vary the timing and 
quantity of left-over doses or skip the dose in the worst case if variations are not possible due to 
medical safety. 
 
Figure 17. Smart medication management system model (Varshney 2013) 
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Section 3.4 Effective Adherence 
The effectiveness of adherence (therapeutic) reduces if there are ‘Dose not Effective’ periods 
in the Pattern of adherence, and in some cases could lead to an appearance of ineffectiveness in 
the therapeutic value of the medicine. Effective Medication Adherence (EMA) is a probability 
measure for assessing the effect of the pattern of adherence due to ‘Dose Not Effective’ periods 
in the prescribed dosing regimen on the effectiveness of adherence.  
If the adherence is 100% of the time to the prescribed interval of taking the doses, EMA will 
be 100%. Any pattern arising from nonadherence should lower the EMA below the 100%. An 
analytical model is developed to study the effect of the patterns of adherence on EMA. This 
research study allows us to validate the operation of this metric under a set of specified 
assumptions.  
Section 3.5 Smart Intervention 
The objective is to improve the adherence of medication; we intend to use ‘EMA’ as a 
construct in our model for deciding ‘when’, and ‘what’ intervention is desirable for 
nonadherence. The design of the intervention based on EMA should allow for predicting when it 
is most likely that intervention will be needed. The decision is made on the fly, in contrast to the 
conventional interventions which work at scheduled intervals. We term intervention based on 
EMA as Smart Intervention for the same reason that it will administer if and when there is a need 
for intervention. ‘What’ intervention will be needed is based on an assessment of factor by which 
the ‘EMA’ will get adversely affected if the patient does not take prescribed medicine at the 
suggest time. This research proposes that medication adherence research should utilize EMA, 
which includes both the pattern and average medication adherence for a patient and therefore, 
can lead to the identification of more effective interventions. Healthcare providers can use the 
 46 
insights from EMA and related medical data to establish customized or revised prescription 
regimen for different groups of patients based on the patterns of medicine intake and clinical 
response to medication. It can also facilitate the design of smart interventions that get 
personalized to the patient’s behavior over a period.  
In this research, an improvement to existing intervention is envisioned that is termed “Smart 
Intervention” to distinguish it from existing intervention. Here, smart intervention mean that 
intervention will be necessary and provided to the patient only if the patient did not consume the 
prescribed self-administered medication dose at the prescribed duration. This smart intervention 
will be affected in the form context-aware reminders to the patient as opposed to simple and 
persistent reminders that existing intervention provides.  
The context-awareness of smart intervention arises from the awareness and consideration of 
DNE events. The decision to administer intervention is then based not only on the prescribed 
interval between the doses but also the presence of the DNE events and the pattern in which 
patient generates the events. Such interventions are provided only when there is a need and are 
more dynamic in nature.  
The possibility that patient will follow the intervention is greater when the intervention is 
discreet, the patient is not being overwhelmed and is cognizant of the justification for 
intervention based on patient’s anomaly in adherence.  
Table 5 shows the functional difference between intervention and smart intervention. 
Intervention Smart Intervention 
Based on AMA Based on EMA 
Simple and Persistent Reminder Context-Aware Reminder 
Table 5. Intervention vs smart intervention 
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This research develops a smart intervention based on BCTs that have underlying theory base 
of Health Behavior Change and upon the Reference Model Architecture for real time systems. 
The system is designed to act at the source of the problem i.e. when the person takes (or skips 
dose at a prescribed time) and generates the probabilistic estimate of the effective medication 
adherence to suggest the next intervention. The impact of the smart intervention on effective 
medication adherence, healthcare cost and the patient outcome could be profound as the problem 
is detected early and action is taken instead of towards the end of medication persistence. 
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Chapter 4. Development 
The development of the conceptual artifact (smart intervention) is the primary contribution of 
this research. This section includes a concise description of the artifact at the appropriate level of 
abstraction (Gregor and Hevner 2013). It describes a general approach for monitoring of 
effective medication adherence. Also, the input parameters used in the analytical model for 
evaluation of the artifact is described in this section. Discussion of parameters along with the 
artifact will provide insight into the relationship between the components of the artifact and the 
new measurement metric for medication adherence, i.e., effective medication adherence (EMA).  
Section 4.1 Constructs 
We started with developing a simplified Model for Medication Adherence based on the 
literature review and the current clinical environment. The dosing regimen begins with 
concordance between the provider who is treating and a patient being treated. In a self-
administered dosing regimen, the patient bears the responsibility to take the medication in 
compliance or adherence with the provided advice. If the provider feels the need to monitor the 
effectiveness of the medication and the symptoms, they may collect the feedback from the 
patient. If all goes well, the therapeutic benefits of the medication are realized towards the end of 
the prescription.  
The study indicates there are number of factors that affect the adherence of the patient to the 
prescribed dosing regimen and thus affect the realization of the therapeutic benefits of the 
medicine(s). Adherence is extent to which a patient’s behavior (regarding taking medication, 
following a diet, modifying habits, or attending clinics) coincides with medical or health advice 
during the period of medication persistence i.e. the time from initiation to discontinuation of 
therapy. Almost invariably, the provider comes to know the outcome of the prescribed 
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medication after the treatment period is over and if the patient provides feedback to the provider. 
If the patient does not self-report, then opportunity to provide timely interventions to improve 
patient’s condition are rare. At the time of prescribing medications to the patient, it is assumed 
that patient will self-report the symptoms if the condition persists beyond a reasonable duration 
of taking the medications.  
In cases where the patient self-reports that symptoms persists, the effectiveness of the 
medication is assessed by discussing with the patient whether they took all the medications on 
the prescribed intervals and estimating the average effectiveness of the doses. Subsequent 
treatment plans may lead to increasing dose persistence for few more days. Figure 18 represents 
the simplified Model for Medication Adherence: 
 
 
Figure 18. Simplified model of medication adherence 
 
Section 4.2 Requirements 
Our requirement is to administer smart intervention i.e. envision a model that provides an 
ability to choose ‘when’ and ‘what’ intervention is needed. We outline the formal requirements 
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of the model for effective medication adherence. The realization of this model is a health IT 
artifact.  
The decision to administer intervention depends on the medication behavior of the patient. 
The medication behavior is event based i.e. if the patient takes the medicines at the prescribed 
intervals over the duration of the prescription. The dosing events can be mapped against a 
timeline for prescribed medication persistence and should ultimately develop a pattern of dosing 
events i.e. the medication behavior. An intervention is a mechanism to control the normal 
medication behavior of patient if he/she does not conform to the prescribed dosing regimen. The 
decision for when an intervention is needed can then be a straightforward rule: if the patient did 
not take the medication at prescribed times, administer the intervention. The simplified model of 
medication adherence can easily be extended to implement this rule if it can capture dosing 
events and the prescribed dosing intervals against a timeline beginning the start of the medication 
and ending end of the medication. We call interventions that are administered based on a 
schedule of prescribed doses as Scheduled Intervention.  
An alarm for a reminder is a good example of scheduled intervention. An alarm can have a 
schedule and can remind of the repeating tasks at specified intervals. When coupled with an 
event capturing system that can register if a task has been performed, alarm for reminder is 
skipped if the task is performed before the next scheduled time. If the task needs to happen 
exactly at the specified interval i.e. exactly at the scheduled time, we have a situation when the 
alarm for the reminder and the task will occur at the same time. The alarm for reminder cannot 
be made to wait for the event unless we decide to schedule the alarm a few moments after the 
time of the task. There is theoretical limit to performing tasks when tasks are interdependent. At 
a time, only one task of the interdependent tasks can be performed. The usefulness of alarm for a 
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reminder is to prompt before the task has to be performed, so as to focus the attention of 
performer. In this situation when we want to have reminder before the task, the alarm is 
scheduled for few moments before the time of the task. The drawback of this is that it does not 
make use of the event capturing system and is repetitive, occurring every time before the 
scheduled task.  
Extending this analogy to deciding when to administer intervention, we arrive at following 
decisive situations: Intervention scheduled before the dosing event, intervention scheduled at the 
same time of dosing event, and intervention scheduled after the dosing event. Interventions 
scheduled before the dosing event always occurs (persistent). Intervention scheduled at or after 
the dosing event is skipped if the dosing event has happened. 
Scheduled Intervention is a prescriptive behavior again, and is determined right at the time of 
prescription. It has little ability to adapt to the medication behavior of the patient because the 
behavior does not exibit at the time of prescription. 
Section 4.3 Model 
We develop the model for effective medication adherence, henceforth also mentioned as 
MEMA, based on effective medication adherence of the patient. In this model, we do not create a 
schedule of administering the interventions but decide the next administration of the intervention 
dynamically. We create a schedule of prescribed dosing events at the time of prescription and 
also register actual dosing event of the patient during prescription. Value for effective medication 
adherence (EMA) generates at each dosing event of the patient and the prescribed dosing event. 
Based on the value of EMA, an appropriate type of intervention is chosen and scheduled either 
before or at the next dosing event for the patient. It may also happen that intervention is not 
deemed necessary for the next prescribed dosing event if the patient is 100% following the 
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prescribed dosing regimen. The type of intervention denotes the priority we associate to the next 
scheduled intervention in maintaining the EMA above a specified threshold (depending on the 
type of care and therapy). Figure 19 shows the priority of the intervention predefined in current 
model as ‘Normal’, ‘Warning’, and ‘High’ based on an allocated probability estimate of EMA 
for the next prescribed dosing event. 
 
Figure 19. Predefined type (priority) of intervention (reminder) (Varshney 2013) 
Deciding the ‘Type of intervention’ requires extensive study of therapy regimens, medication 
behaviors, and medical conditions. Developing classification specific to prescriptions can 
become an active research topic. 
MEMA model is more adapted to the medication behavior of the patient as it keeps up with 
the actual dosing events and also provides the ability to decide what intervention is needed. 
Figure 20 shows the model for effective medication adherence (MEMA). 
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Figure 20. Detailed design of model for effective medication adherence (MEMA) 
Figure 20 shows the model for effective medication adherence (MEMA). This model is for 
use by the healthcare provider and complements the prescriber’s role in improving the 
medication adherence. The relationship between the healthcare provider and patient is the basis 
for operationalization of this model. The patient can opt in for smart interventions for a 
prescription drug. Upon consent, the medication behavior of the patient is monitored using 
Medication Event Monitoring System (MEMS) and at every dose event, the information is 
relayed to the Smart Medication Management System (SMMS).  
The MEMA implementation of RMA node for smart intervention as depicted in Figure 16 is 
a component based on smart medication management system. It can record the dosing event, and 
decide if the dosing event is a prescribed dose event, undesirable dose event or dose not effective 
event. Based on the outcome, the system can either decide to calculate the effective medication 
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adherence value (using dose not effective), or notify the healthcare provider (undesirable dose 
event), or calculate EMA and decide to do nothing (prescribed dose event). If the predicted value 
of EMA is deemed to fall below a certain value specified for the therapy persistence, the system 
will schedule an intervention for the next dosing interval. The frequency and type of intervention 
for the next prescribed dosing event is decided based on the value of EMA and pattern of 
medication adherence exhibited by the patient in the past.  
The MEMA model is implemented as having a systems interface and a user interface. The 
systems interface is for the administrator while there are two types of user interface for provider 
and the patient. The user interface can be affected via web based, smartphone or desktop 
application. The ability to connect over wireless/internet is requirement for the system to operate. 
Section 4.4 Design 
 
Figure 21. Model of medication adherence 
Figure 21 shows a simplified model of medication adherence. We enhance the existing model 
to include the wireless medication box (WMB), and the application logic of medication 
management server (MMS) is enhanced based on the Resource Model Architecture to include 
the state of the system (world view).  
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In the model for effective medication adherence shown in Figure 22, both the patient and 
healthcare provider interact with the medication adherence application, which interacts with 
medication management server through a variety of wireless networks. The mobile application 
interacts with the healthcare provider and the patient. The mobile application also interacts with 
the medication management server to keep track of prescriptions provided by the healthcare 
providers’ office as well as the consumption of medication by the patient. The IT supports these 
interactions and tracking as part of implementing the intervention for medication adherence. 
More specifically, medication management server keeps track of adherence, side effects, and 
dosing changes which are available through mobile applications based on the reminders provided 
to the patient and patient’s response to reminders. Also, medication management server keeps 
track of dose consumption and information available through wireless technologies which 
provide the prescribed doses to the patient. Finally, based on the interactions with mobile 
applications, patients, and healthcare providers, medication management server will generate the 
context-aware reminder for the patient. This process continues until the desired rate of effective 
medication adherence is achieved. We expect that many more applications on Smartphone and 
other smart systems using wireless technologies will become available for improving medication 
adherence.  
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Figure 22. Model for effective medication adherence (MEMA) 
The high level view showing variables used in the analytical model mapped to MEMA is 
represented in Figure 23. Healthcare provider enters the prescription information (λ, NPRES) using 
mobile application, which is eventually saved in the medication management server (MMS) and 
shared with patient through the mobile application. Patient opens the wireless medication box to 
consume the prescribed dose. Dose information (NTAKEN) and the dispensing and consumption 
information (NTAKEN, λ). is reported to the MMS. Using the adherence information MMS 
performs the analysis of consumption and calculates the EMA and UDE for different scenarios 
(nor reminders, simple and persistent reminders, and context-aware reminders). Based on the 
analysis of consumption, smart interventions (CAR, NP, NR, PD-R, PND-R) are generated and 
provide to the patient to maintain the medication adherence as prescribed by the healthcare 
provider. If patient misses a dose (NMISSED) it is reported to the healthcare provider and 
healthcare provider provides the advice/scheduling based on the current EMA. On the other 
hand, if patient consume more than desirable doses (UDE) during the prescribed interval it is 
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reported to the healthcare provider too. However, no intervention is provided in the case of 
undesirable dose event (UDE). Smart interventions for UDEs will developed in future study.  
 
Figure 23. Variables in model for effective medication adherence (MEMA) 
 
Section 4.5 Verification 
The operation of MEMA is verified using the steps: 
1. Design a mobile application for medication adherence (MMA) 
2. Utilize a smart medication dispenser that can dispense doses as necessary (WMB) 
3. Design a Server (MMS) that 
• Can communicate with patient and healthcare providers (via mobile application) as 
needed and also with medication dispenser 
• Can receive necessary dose consumption information from smart dispenser and/or the 
patient and can process medication consumption context of the patient 
• Can generate simple and persistent, and context-aware reminders (decide when to 
send reminders and how often) 
• Can analyze the consumption history and communicate with healthcare provider 
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4. Provide multi-network wireless access to various components (device, server) to support 
patient mobility 
5. Check if various components (mobile medication application, mobile management server and 
wireless medication box) can interact with each other and with patient and healthcare 
provider 
6. Check if medication management server receives informational contents 
7. Check if context generates correctly 
8. Check the timing of reminders and context-aware reminders 
9. Check the number of doses, reminders and consumption history for any inconsistencies 
Figure 24a shows the operation of MEMA. Figure 24b represents the algorithm to determine 
when and how to generate reminders to patients. 
 
 
Figure 24a. The operation of the MEMA 
Receive information on medications, doses, 
adherence goals, type of reminders 
Receive information on the type and duration 
of medication monitoring 
Analyze the Pattern of Adherence
Is Dose taken?
Yes
Determine when and how (smartphone, monitor, 
display board) to generate reminders to patients
No
Communicate to Healthcare Professionals 
Communicate with dispenser/patient about 
medications at certain times
Generate context-
aware Reminder(s)
Yes
Is it safe to
take dose now?
No
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Obtain dosing information 
If time>=due-dose-time 
If Intervention = simple reminder 
If (time-limit-reminder = Not-expired) 
Display a reminder on patient’s preferred device 
Obtain patient-dose-input 
If status-dose = taken 
Update med-consumption-history (attempts, dose status, timing, quantity) 
Else if (message-to-HP = allowed) Inform HP 
 Else If intervention = persistent reminder 
While (status-dose =not-taken) and (time-limit-reminder = Not-expired)  
If (number-of reminder-current-dose <Limit-persistence) 
Display a reminder on patient’s preferred device 
Obtain patient-dose-input 
If status-dose = taken 
Update med-consumption-history (attempts, dose status, timing, quantity) 
Else If (message-to-HP = allowed) Inform HP 
Else If intervention = context-aware reminder 
Process medication-consumption-history 
If (Status-due-dose= Already-taken)   
No reminder 
Else 
While (status-due-dose =not-taken) and (time-limit-reminder = Not-expired)  
If (number-of reminder-current-dose <Limit-persistence) 
Display a reminder on patient’s preferred device 
Obtain patient-dose-input 
If status-dose = taken 
Update med-consumption-history (attempts, dose status, timing, quantity) 
Else If (message-to-HP = allowed) Inform HP 
 Record the actions (attempts, dose status and times) 
Update medication consumption history 
Figure 24b. The algorithm to determine reminder generation 
Table 6 lists the role of the model in various cases of nonadherence. The model currently 
supports reminders as an intervention and can be extended to include educational interventions 
for patients to address other reasons for nonadherence.   
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 Primary Reason for 
Nonadherence 
Suitable Intervention Model’s Role in the 
Intervention 
Case 1 Busy lifestyle Reminders Currently Supported 
Case 2 Cognitive Decline Reminders Currently Supported 
Case 3 Side Effects Educational Can be expanded  
Case 4 Complexity of Regimen Reminders/Educational Can be expanded 
Case 5 Length of chronic condition Family Support Can be expanded 
Case 6 Cost of medications Financial Intervention Difficult to expand 
Case 7 Lack of knowledge Educational Intervention Can be expanded 
Case 8 Lack of trust / perceived need Behavioral Interventions Difficult to expand 
Table 6. Nonadherence cases and the model’s role in the intervention 
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Chapter 5. Evaluation of Process 
Design science research (DSR) includes the building/design of an artifact as well as the 
evaluation of its use and performance (Pries-Heje et al. 2007; Vaishnavi et al. 2007). The model 
is evaluated using formal proofs and expert interviews (Cleven et al. 2009; Gregor and Hevner 
2013; Parsons and Wand 2008). Evaluation with formal proofs such as analytical model 
represents an adequate evaluation method for DSR models (March and Storey 2008). The ex-
ante perspective, i.e., artificial evaluation methods will help us to control the potential 
confounding variables more carefully and to prove or disprove the design propositions, design 
theories, and the utility of the developed artifact (Pries-Heje et al. 2008). Evaluations of an 
artifact based on formal proofs facilitate the assessment of a solution’s suitability for a certain 
problem by implementing the solution generically. 
The artifact is further evaluated (empirically) to demonstrate its worth with evidence 
addressing criteria such as validity, utility, quality, and efficacy (Gregor and Hevner 2013). 
Domain experts (healthcare providers and health IT experts) have compared the smart 
intervention with the existing interventions to evaluate the model. We have focused explicitly on 
the experts' reasoning about their preferences after comparing the simple and the smart 
interventions, and on relating that to the proposed health IT artifact. This evaluation provides the 
insights for interventions preferred by experts. 
Section 5.1 Analytical Model 
Analytical modeling is relevant, suitable, and useful for this work. Analytical models have 
been used as formal proofs for a long time to derive performance of systems in Computer 
Science, Decision Science, Operations Research, and Engineering (Saaty and Vargas 2012). 
These models provide several important insights into the design and operation of artifacts and 
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can be used to improve the design and operation of the artifact in an iterative fashion. In some 
sense, they provide intermediate and immediate results, which can help improving the design of 
artifacts, without waiting for subsequent empirical/multi-method studies. Many times, analytical 
models will help to validate the design by providing results that conform to expected 
performance of the artifact. We believe that analytical models could be used effectively in the 
design science area for both preliminary and intermediate evaluation of artifacts, followed by a 
more empirical evaluation.  
We should be aware of numerous limitations and challenges in analytical models. The 
development of models may take time especially when the artifact's design and operation are still 
evolving. Many times, it is not clear what variables and metrics to include and what parameters 
to utilize and where to get those values from. The choice of model type is another challenge as a 
decision on whether to use deterministic (closed-form) or stochastic (random-events) approach 
can affect the suitability and usefulness of the model. The underlying assumptions in the model 
along with difficulty in validation, especially with error propagation inherent in some models, 
could reduce the usability of analytical models. The complexity of models in deriving accurate 
results is another challenge.  
We evaluate the performance of smart interventions by MEMA by using the analytical model 
as shown in Figure 25. The approach we take in our research is to develop a simple model for the 
results that can help verify the basic design and operation of the model and more complex 
models that can provide a deeper understanding and more accurate results. In the design of 
computing and communications systems, such models have been used for a long time due to 
their ability to express complex relationships among many variables or behavior of interests. We 
expect that the comprehensive model, although complex, will be useful in predicting artifact’s 
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performance. One of the challenges has been the level of complexity in developing models and 
subsequent computations. 
 
Figure 25. The use of analytical model in artifact evaluation 
To address this, a model of reasonable complexity has been introduced to provide accurate 
results. Therefore, for evaluation of interventions for medication adherence, mathematical 
models are both suitable and desirable. More specifically, we measure the impact of various 
designed solutions and effect of multiple interventions on the rate of achievable medication 
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adherence. The model is developed using relationships among several independent (input) 
variables and dependent (output) variables discussed in Table 7.  
To study patterns of adherence and effective medication adherence (EMA), we considered 
two distributions a) Uniform distribution, and 2) Poisson distribution. The goal is to analyze the 
pattern of adherence for a patient by utilizing the events when the patient takes the doses. We 
derive the probabilities of not being medically effective and not being safe. Patients with enor-
mously diverse dosing behavior (random, skip followed by catch up, drug holidays, and multiple 
doses) can achieve the same average levels of medication adherence. Also, some patients with 
lower average adherence achieve more or less same outcomes as patients with higher average 
adherence (Sokol et al. 2005). The similar outcomes with different levels of adherence raise the 
possibility that patterns of adherence have something to do with the effectiveness of medication 
adherence. If the minimum time (TMIN) between two doses is not medically safe, then it will lead 
to UDE. On the other hand, if the maximum time (TMAX) between two doses is not medically 
effective then it will lead to dose not effective (DNE). This study focuses on studying the 
patterns of adherence along with average medication adherence (AMA), as effective medication 
adherence (EMA).  
We started with Uniform distribution to study adherence. However, after comparing the 
results of both Uniform and Poisson distributions to study adherence, we observed that the 
differences are not huge. On the other hand, we felt that Poisson represents more variance and 
also there is evidence that medication consumption by people is closer to Poisson (Knafl et al. 
2004). So, we decided to use Poisson distribution for the evaluation of MEMA using analytical 
model. The uniqueness of analytical model is that it can estimate EMA for many possible 
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scenarios. The scenarios are including and excluding the interventions for computing EMA. 
These different scenarios affect the ability to take medications. 
5.1.1 Assumptions 
A model is needed because data is not available on exact times patients have consumed 
various doses. Such data will become available in future. So for now, we make use of the 
analytical model to study/compare different interventions and their effectiveness. The model will 
evaluate effective medication adherence (EMA) as opposed to average medication adherence 
(AMA) in different scenarios and interventions. Several assumptions were made to keep the 
analytical model reasonably accurate. The analytical model assumes the following: 
Assumption 1: The patients are in independent living and thus manage their medications.  
Assumption 2: The dose concentration in the human body declines with time and reaches below 
a threshold at the certain maximum interdose-time. A medication dose taken beyond maximum 
interdose-time has reduced/negligible medical effectiveness. 
Assumption 3: Taking more doses over time or too many doses at the same time does not 
improve medication adherence or health outcomes. 
Assumption 4: The patients are willing to take medicine, but are not able to due to scheduling 
difficulties, forgetfulness, or cognitive challenges.  
Assumption 5: The interventions used in the form of simple and persistent reminders, and 
context-aware reminders. 
Assumption 6: The interventions cannot be used for unwilling patients at present.  
5.1.2 Design 
The basic input parameters of the model are dosing rate (λ), probability of taking dose due to 
reminder (PD-R), probability of not taking dose due to reminder (PND-R), number of persistent 
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reminders (NP), number of reminders in a day (NR), overdose time (t), time at which I
th dose is 
taken (TI), time at which I+1
th dose is taken (TI+1), minimum time between any two doses to 
remain medically safe (TMIN), maximum allowed time between any two doses to remain 
medically effective (TMAX). The output parameters are effective medication adherence (EMA) 
with and without interventions, healthcare cost (HCCOST), and side effects (UDE). Table 7 
represents the summary of all the parameters used for developing the analytical model. 
Notation Meaning 
NPRES Number of prescribed doses over given time 
NTAKEN Number of doses taken by the patient 
NMISSED Number of doses missed by the patient 
λ Ideal rate of dose consumption event (dose/hour) 
T Observed time 
TI Time at which Ith dose is taken 
TI+1 Time at which I+1th dose is taken 
TMAX Maximum allowed time between two doses to remain medically effective 
TMIN Minimum time between two doses to remain medically safe 
AMA Average Medication Adherence 
AMANEW-SR Average Medication Adherence due to simple and persistent reminder 
AMANEW-CAR Average Medication Adherence due to context-aware reminder 
NP Number of reminders per missing dose event 
NR Number of reminders in a day (one per dose) 
Q Number of reminders that came during the last TMAX 
M Multiple medications with multiple doses prescribed in a day 
PD-R Probability of taking dose due to reminder 
PND-R Probability of not taking dose due to reminder 
NR No reminder 
SR Simple and persistent reminder 
CAR Context-aware reminder 
DNE Dose not effective 
UDE Undesirable dose event 
EMA Effective Medication Adherence 
EMANR Effective Medication Adherence for no interventions 
EMASR Effective Medication Adherence for simple and persistent reminder 
EMACAR Effective Medication Adherence for context-aware reminder 
UDEBASE Probability that the gap between doses is less than TMIN 
UDESR UDE in case simple and persistence reminders 
UDETOTAL Probability that the gap between doses is less than TMIN 
HCCOSTNA Healthcare cost in case of nonadherent 
HCCOSTSR Healthcare cost in case of simple and persistent reminder 
HCCOSTCAR Healthcare cost in case of context-aware reminder 
HCCOST-PAST Disease related healthcare cost (Medical cost + drug cost) 
INTVNCOST-SR Cost of interventions for simple and persistent reminder 
INTVNCOST-CAR Cost of interventions for context-aware reminder 
 
Table 7. Analytical model parameters/variables 
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We present known relationships among variables and derive new relationships. These will 
help us in evaluating output variables such as Effective Medication Adherence (EMA), 
Healthcare cost (HCCOST), and Undesirable dose event (UDE) under different scenarios and 
interventions. Different scenarios and interventions are considered to analyze the difference 
between the outcome of smart interventions/context-aware reminder (CAR), simple 
interventions/simple and persistent reminder (SR) and no interventions/no reminder (NR). 
5.1.2.1 Measuring effective medication adherence – Single medication, multiple doses daily 
The average medication adherence during an observed period of prescribed self-administered 
medication can be given by 
𝐀𝐌𝐀 =  (𝐍𝐓𝐀𝐊𝐄𝐍/𝐍𝐏𝐑𝐄𝐒)        (1) 
NPRES is the number of prescribed doses over the given time and is given as NTAKEN+NMISSED. 
NTAKEN and NMISSED are the number of doses taken and the number of doses missed by the 
patient, respectively. The adherence level can have any value between 0 to 100%, both included. 
In rare cases, adherence level exceeds 100% if the patient took more doses than prescribed.  
The time variations between doses are also important in evaluating the medical effectiveness 
of doses. The probability that the gap between doses has exceeded the maximum interdose-time 
is found using ideal dosing rate (λ) and TMAX for a particular event k. Hence, the probability that 
I+1th dose not effective (DNE) is expressed as 
𝐃𝐍𝐄 = 𝐏𝐫𝐨𝐛((𝐓𝐈+𝟏 − 𝐓𝐈) > 𝐓𝐌𝐀𝐗) = (𝛌𝐭)
𝐤 ×
𝐞−𝛌𝐭
𝐤!
 𝐟𝐨𝐫 𝐤 = 𝟎 𝐚𝐧𝐝 𝐭 = 𝐓𝐌𝐀𝐗  (2) 
TMAX is the maximum allowed time between any two doses to remain medically effective; λ is 
the ideal rate of dose consumption event, and t is the observed time.  
Undesirable Dose Event (UDE) is the likelihood of events when the patient takes doses that 
are too close to each other, possibly resulting in toxicity and side effects, which in turn can 
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reduce the motivation for taking medications in future. UDEBASE is the probability that the gap 
between doses is less than the minimum interdose-time. 
𝐔𝐃𝐄𝐁𝐀𝐒𝐄 = 𝐏𝐫𝐨𝐛((𝐓𝐈+𝟏 − 𝐓𝐈) < 𝐓𝐌𝐈𝐍) = (𝛌𝐭)
𝐊 × 
𝐞−𝛌𝐭
𝐤!
 𝐟𝐨𝐫 𝐤 = 𝟐 𝐚𝐧𝐝 𝐭 = 𝐓𝐌𝐈𝐍   (3) 
TMIN is the minimum interdose-time to remain medically safe, and λ is the ideal dosing rate 
(dose/hour).  
Effective Medication Adherence (EMA) depends on both the average medication adherence 
and the pattern of adherence. Out of the two patterns identified in equations 2 and 3, when doses 
are far apart, the effectiveness of the doses is reduced. Taking doses too closely may not improve 
the effectiveness due to the potential for side effects or overdose, which may reduce medication 
adherence over time. Therefore, we model EMA to include pattern only when doses are far apart. 
Thus, Effective Medication Adherence can be given as  
𝑬𝑴𝑨 = 𝑨𝑴𝑨 × (𝟏 − 𝑫𝑵𝑬) = 𝑨𝑴𝑨 × (𝟏 − 𝒆−𝛌𝐓𝐌𝐀𝐗)      (4) 
Since we model EMA to be between 0 and 100%, and as in some cases, AMA can exceed 
100% where patients are trying to catch up or taking more doses than prescribed. For these cases, 
the EMA is normalized as 
𝑴𝒊𝒏(𝑨𝑴𝑨 × (𝟏 − 𝒆−𝝀𝑻𝑴𝑨𝑿), 𝟏). 
Analyzing equations 2, 3 and 4 we can see that EMA is a better predictor for measuring the 
medication adherence as compared to AMA. As someone can take all doses in a short period 
with much worse health outcomes. 
Scenarios 
In this section, we consider three different scenarios for the reminders. Figure 26  shows the 
considered scenarios (a) without any intervention, (b) with simple and persistent reminders and 
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(c) with context-aware reminders. We discuss each of these along with corresponding equations 
for EMA, UDE, and HCCOST. 
 
Figure 26. Different scenarios without intervention and with interventions 
Scenario 1: Without any Intervention – NR 
In this scenario, we compute the EMA keeping in consideration that no intervention/reminder 
is sent to the patient, and the patient takes doses by his/her choice and convenience. It shows that 
the patient did not follow the prescribed self-administered medication. Varshney and Singh 
(2013) have represented that memoryless distributions such as exponential distribution are 
suitable for medication consumption. Such behavior is observed in practice (Knafl et al. 2004). 
The EMA for no interventions is computed as 
𝑬𝑴𝑨𝑵𝑹 = 𝑨𝑴𝑨 × (𝟏 − (𝛌𝐭)
𝐤 ×
𝐞−𝛌𝐭
𝐤!
 𝐟𝐨𝐫  𝐭 = 𝐓𝐌𝐀𝐗)     (5) 
𝑶𝒓  𝑬𝑴𝑨𝑵𝑹 = 𝑨𝑴𝑨 × (𝟏 − 𝒆
−𝛌𝐓𝐌𝐀𝐗) 
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λ is given as (𝐴𝑀𝐴 ×
𝑁𝑅
24
). 
Since the patient is not following the prescribed self-administered medication in this 
scenario, it might lead to Undesirable Dose Event (UDE). UDE is as follows: 
𝑼𝑫𝑬𝑩𝑨𝑺𝑬 = 𝑷𝒓𝒐𝒃((𝑻𝑰+𝟏 − 𝑻𝑰) < 𝑻𝑴𝑰𝑵) =
𝟏
𝟐
× (𝛌𝐓𝐌𝐈𝐍)
𝟐 × 𝐞−𝛌𝐓𝐌𝐈𝐍    (6) 
We will analyze and compare EMANR in the results section.  
Scenario 2: With Simple and Persistent Reminders – SR 
In this scenario, simple and persistent reminders are provided to the patient at the due time of 
the doses. Here, persistence refers to the repetitiveness of reminder. In this case, the average 
adherence and pattern of adherence both may be changed. We will have to study both.  
In this case, the patient is following a combination of two patterns: random and deterministic. 
So the patient may take doses as before using Poisson distribution and may also take doses based 
on reminders. This results in several combinations of patterns for adherence. However, we are 
interested in finding out the probability that the gap between doses has exceeded the maximum 
interdose-time (TMAX) and probability that the gap between doses is less than the minimum 
interdose-time (TMIN).   
The probability that the gap between doses has exceeded the maximum interdose-time is 
approximated (for simplification) as follows. At any time, the probability will be a product of 
two probabilities: the probability that the patient did not take any dose in last TMAX time and 
probability that the patient did not take any dose "after all the reminders that came during the last 
TMAX".  
𝐏𝐫𝐨𝐛((𝐓𝐈+𝟏 − 𝐓𝐈) > 𝐓𝐌𝐀𝐗) = (𝑷𝑵𝑫-𝑹)
𝑸 × [𝒆−𝛌𝐓𝐌𝐀𝐗]         (7) 
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Q is the number of reminders that came during the last TMAX and is given as 
𝑇𝑀𝐴𝑋
24
𝑁𝑅
 . PND-R is 
the probability that the patient does not take the dose based on the reminder and is computed as 1 
- PD-R, where PD-R is the probability of consuming dose due to reminder. NR is the number of 
reminders in one day (or a number of doses in a day). The simple and persistent reminders are 
not based on if the patient has taken the dose recently on his/her own. So average medication 
adherence (AMA) in case of simple and persistent reminders can be given as 
𝐀𝐌𝐀𝐍𝐄𝐖-𝐒𝐑 = 𝐌𝐢𝐧[(𝐀𝐌𝐀 + (𝟏 − 𝐏𝐍𝐃-𝐑) × 𝛌 × 𝐓𝐌𝐀𝐗), 𝟏]    (8) 
Moreover, the effective medication adherence for simple and persistent reminders can be 
computed as follows 
𝐄𝐌𝐀𝐒𝐑 = 𝐀𝐌𝐀𝐍𝐄𝐖-𝐒𝐑  (𝟏 − (𝐏𝐫𝐨𝐛((𝐓𝐈+𝟏 − 𝐓𝐈) > 𝐓𝐌𝐀𝐗))) 
Using the value of Prob((TI+1 − TI) > TMAX) from equation 7, EMASR is represented as 
𝐄𝐌𝐀𝐒𝐑 = 𝐀𝐌𝐀𝐍𝐄𝐖-𝐒𝐑  (𝟏 − ((𝑷𝑵𝑫-𝑹)
𝑸 × [𝒆−𝛌𝐓𝐌𝐀𝐗] ))        (9) 
On the other hand, the probability that the gap between doses is less than the minimum 
interdose-time would need to include two factors. One is the probability that someone took two 
doses in last TMIN time, and the other is that someone took one dose in last TMIN time on his or 
her own and took another dose due to the reminder. However, we will have to multiply 2nd 
factor by the probability that a reminder even came during TMIN time and can be given as 
𝑇𝑀𝐼𝑁
24
𝑁𝑅
. 
If TMIN is too small, then no reminder may come during TMIN. Hence, the probability of two 
doses taken in less than TMIN time is the sum of the probability of patient taking two doses when 
no reminder came and the probability that patient consumes a dose along with a dose due to the 
reminder.  
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The above possibility can raise adherence level and also improve the pattern in some cases. 
On the other hand, it may result in undesirable dose event (UDE). The UDE can occur when the 
patient has already taken the medicine at scheduled time and also consumes medicine when the 
reminder arrives for the same dose. UDETOTAL or the probability that the gap between doses is 
less than the minimum interdose-time is 
𝑼𝑫𝑬𝑻𝑶𝑻𝑨𝑳 = 𝑷𝒓𝒐𝒃((𝑻𝑰+𝟏 − 𝑻𝑰) < 𝑻𝑴𝑰𝑵) 
= [𝟏 − (
𝑻𝑴𝑰𝑵
𝟐𝟒
𝑵𝑹
)] × [(𝛌𝐭)𝐤 ×
𝒆−𝛌𝐭
𝒌!
 𝒇𝒐𝒓 𝒌 = 𝟐, 𝒕 = 𝑻𝑴𝑰𝑵] +
𝑻𝑴𝑰𝑵
𝟐𝟒
𝑵𝑹
× 𝑷𝑫-𝑹
× [(𝛌𝐭)𝐤 ×
𝒆−𝛌𝐭
𝒌!
 𝒇𝒐𝒓 𝒌 = 𝟏, 𝒕 = 𝑻𝑴𝑰𝑵] 
= [𝟏 − 𝛌𝐓𝐌𝐈𝐍] × [(𝛌𝐓𝐌𝐈𝐍)
𝟐 ×
𝒆−𝛌𝐓𝐌𝐈𝐍
𝟐!
] +  𝛌𝐓𝐌𝐈𝐍 × 𝑷𝑫-𝑹 × [(𝛌𝐓𝐌𝐈𝐍) × 𝒆
−𝛌𝐓𝐌𝐈𝐍] (10) 
The intervention is capable of changing the gap between doses due to simple and persistent 
reminders. This may lead to higher UDE. In this possibility, both the pattern and adherence level 
go up unless patient's probability of taking doses is zero along with zero AMA. The new 
adherence can be more than 100% if the patient follows reminders and has access to more doses 
than just the daily doses. It can also increase UDE, but will improve interdose-time.  
𝑼𝑫𝑬𝑺𝑹 = 𝑼𝑫𝑬𝑻𝑶𝑻𝑨𝑳 − 𝑼𝑫𝑬𝑩𝑨𝑺𝑬       (11) 
Scenario 3: With Context-Aware Reminders - CAR 
In this scenario, the patient is sent context-aware reminders based on the consumption of 
doses and the due time of dose. More specifically, context-aware reminders keep track of doses. 
The context-aware reminders do not generate a dosing rate of their own as the reminders 
generates only when the dose (that was due) is missed. So the patient will not run out of doses 
due to the context-aware reminders.  
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𝑷𝒓𝒐𝒃((𝑻𝑰+𝟏 − 𝑻𝑰) > 𝑻𝑴𝑨𝑿) = [(𝑷𝑵𝑫-𝑹)
𝑻𝑴𝑨𝑿
𝟐𝟒
𝑵𝑹 ]
𝑵𝑷
× [(𝛌𝐭)𝐤 ×
𝒆−𝛌𝐭
𝒌!
 𝒇𝒐𝒓 𝒌 = 𝟎, 𝒕 = 𝑻𝑴𝑨𝑿] (12) 
NR is the number of reminders and NP is the number of reminders per missing dose event 
(persistence or continuity of the reminders). The optimal value of NP can be decided based on 
patient's preferences and abilities, the amount of overhead in generating a reminder among other 
factors.   
The AMA level will also go up as the patient is taking some doses after context-aware 
reminders. The new value of average medication adherence is  
𝑨𝑴𝑨𝑵𝑬𝑾-𝐂𝐀𝐑 = 𝑴𝒊𝒏 [(𝑨𝑴𝑨 + (𝟏 − 𝑷𝑵𝑫−𝑹) + (𝑷𝑵𝑫−𝑹)(𝟏 − 𝑷𝑵𝑫−𝑹)
+ (𝑷𝑵𝑫−𝑹)
𝟐(𝟏 − 𝑷𝑵𝑫−𝑹) + ⋯ (𝑷𝑵𝑫−𝑹)
𝑵𝑷−𝟏(𝟏 − 𝑷𝑵𝑫−𝑹)) , 𝟏] 
𝑨𝑴𝑨𝑵𝑬𝑾-𝑪𝑨𝑹 = 𝑴𝒊𝒏[(𝑨𝑴𝑨 + (𝟏 − 𝑷𝑵𝑫−𝑹)
𝑵𝑷)), 𝟏]        (13) 
𝑬𝑴𝑨𝑪𝑨𝑹 = 𝑨𝑴𝑨𝑵𝑬𝑾-𝐂𝐀𝐑 (𝟏 − [(𝑷𝑵𝑫−𝑹)
𝑻𝑴𝑨𝑿
𝟐𝟒
𝑵𝑹 ]
𝑵𝑷
× [( 𝛌𝐭)𝐤 ×
𝒆−𝛌𝐭
𝐤!
 𝒇𝒐𝒓 𝒌 = 𝟎, 𝒕 = 𝑻𝑴𝑨𝑿]) 
= 𝑨𝑴𝑨𝑵𝑬𝑾-𝐂𝐀𝐑(𝟏 − (𝑷𝑵𝑫−𝑹)
𝛌𝐓𝐌𝐀𝐗  ]
𝑵𝑷
 × [ 𝒆−𝛌𝐓𝐌𝐀𝐗])         (14) 
 
If the patient already took two doses very close to each other, there will be no context-aware 
reminders. In that sense, a context-aware reminder will not increase the probability of 
undesirable dose event (UDE). Therefore, the undesirable dose event probability (UDEBASE) can 
still be given as 
𝐔𝐃𝐄𝐁𝐀𝐒𝐄 = 𝐏𝐫𝐨𝐛((𝐓𝐈+𝟏 − 𝐓𝐈) < 𝐓𝐌𝐈𝐍) = (𝛌𝐓𝐌𝐈𝐍)
𝟐 ×
𝐞−𝛌𝐓𝐌𝐈𝐍
𝟐!
    (15) 
5.1.2.2 Healthcare cost and interventions 
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Medication nonadherence increases the healthcare cost by $100-300 billion per year (NEHI 
2009). To see how smart interventions minimizes the healthcare cost we have derived following 
relationships for all three different scenarios a) without any intervention, b) simple and persistent 
reminder, and c) context-aware reminder. 
In the case of nonadherent patients who does not receive any intervention and consume doses 
as per their choice/convenience, their healthcare cost comprises of medical cost and drug cost, 
i.e., the all-disease cost. So, healthcare cost for nonadherent patients is calculated as follows: 
𝐇𝐂𝐂𝐎𝐒𝐓𝐍𝐀 = (𝐇𝐂𝐂𝐎𝐒𝐓-𝐏𝐀𝐒𝐓) × (𝟏. 𝟎𝟓)
𝐍       (16a) 
where N represents the Nth year from the year of data. 
If the patient receives simple and persistent reminders to comply with the prescribed dosing 
regimen, then in addition to the all-disease cost they have to pay for the intervention cost. As 
well as there will be some additional cost due to undesirable dose events. Therefore, we derive 
the healthcare cost in case of simple and persistent reminders as 
𝐇𝐂𝐂𝐎𝐒𝐓𝐒𝐑 = (𝐇𝐂𝐂𝐎𝐒𝐓-𝐏𝐀𝐒𝐓) × (𝟏. 𝟎𝟓)
𝐍 × (𝟏 + 𝐔𝐃𝐄𝐒𝐑) + 𝐈𝐍𝐓𝐕𝐍𝐂𝐎𝐒𝐓-𝐒𝐑  (16b) 
In the case of context-aware reminder, there will be all-disease cost and the cost for the 
context-aware reminder. However, there will not be any additional cost for undesirable dose 
event. Because context-aware reminder does not lead to additional UDE as represented in 
equation 15. Therefore, we drive the healthcare cost due to context-aware reminder as  
𝐇𝐂𝐂𝐎𝐒𝐓𝐂𝐀𝐑 = (𝐇𝐂𝐂𝐎𝐒𝐓-𝐏𝐀𝐒𝐓) × (𝟏. 𝟎𝟓)
𝐍 + 𝐈𝐍𝐓𝐕𝐍𝐂𝐎𝐒𝐓-𝐂𝐀𝐑     (16c) 
Therefore, from equation 16b and 16c we can see that the healthcare cost due to simple and 
persistent reminders includes the additional cost for UDE as compared to healthcare costs due to 
the context-aware reminder. Also, the intervention cost (INTVNCOST) varies for context-aware 
reminders as compared to the simple and persistent reminder. 
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Equations 1 through 15 represents the analytical model for prescribed self-administered 
medication of single medication in a day. The following section represents the analytical model 
for prescribed self-administered medication of multiple medications in a day. These multiple 
medications are independent of each other. 
5.1.2.3 Measuring effective medication adherence – Multiple medications, multiple doses daily 
 
Scenario 1: Simple and Persistent Reminders - SR 
Let us assume,  
 km is the event 
 NRm is Number of prescribed doses in a day for mth medicine 
 λ m is the average arrival rate for mth medicine  
 where, λm =
NRm
24
 
 T(MAX)m is time (tm) observed for mth medicine 
 P(D-R)m is the Probability of taking dose due to reminder for mth medicine 
 P(ND-R)m is the Probability of not taking dose due to reminder for mth medicine 
𝑷(𝑵𝑫-𝑹)𝒎 = 𝟏 − 𝑷(𝑫-𝑹)𝒎        (17) 
 Qm is the number of reminders came in during last T(MAX)m for mth medicine 
𝑸𝒎 =
𝑻(𝐌𝐀𝐗)𝐦
𝟐𝟒
𝑵𝑹𝒎
         (18) 
 Probability of number of doses in the last T(MAX)m for mth medicine, i.e., Prob(NRm) is  
𝐏𝐫𝐨𝐛(𝐍𝐑𝐦) = (𝐏(𝐍𝐃-𝐑)𝐦)
𝐐𝐦        (19) 
 Mean 𝛍𝐦 = 𝛌𝐦 × 𝐭𝐦         (20) 
 Probability of number of doses after the last reminder, i.e., Prob(km) is  
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𝑷𝒓𝒐𝒃(𝒌𝒎) =
[𝝁𝒎
𝒌𝒎×𝒆−µ𝒎]
𝒌𝒎!
        (21) 
Multiplying equation 19 and 21 we get the probability that the gap between doses exceeded 
the maximum interdose-time, i.e., the dose is not effective (DNE). Therefore,  
𝐷𝑁𝐸𝑚 = 𝑃𝑟𝑜𝑏[(𝑇(𝐼+1)𝑚 − 𝑇(𝐼)𝑚) > 𝑇(𝑀𝐴𝑋)𝑚] =  (P(ND-R)m)
Qm × 𝑃𝑟𝑜𝑏(𝑘𝑚) 
𝑫𝑵𝑬𝒎 = 𝑷𝒓𝒐𝒃[(𝑻(𝑰+𝟏)𝒎 − 𝑻(𝑰)𝒎) > 𝑻(𝑴𝑨𝑿)𝒎] =  (𝐏(𝐍𝐃-𝐑)𝐦)
𝐐𝐦 ×
[𝝁𝒎
𝒌𝒎×𝒆−µ𝒎]
𝒌𝒎!
 (22) 
We Know, 𝐴𝑀𝐴𝑚 = 𝑁𝑚(𝑇𝑎𝑘𝑒𝑛)/𝑁𝑚(𝑃𝑟𝑒𝑠) 
𝑨𝑴𝑨(𝒏𝒆𝒘-𝑺𝑹)𝒎  = 𝑴𝑰𝑵[(𝑨𝑴𝑨𝒎 + 𝑷(𝑵𝑫-𝑹)𝒎 × 𝑸𝒏), 𝟏]    (23) 
𝐸𝑀𝐴(𝑆𝑅)𝑚 = 𝐴𝑀𝐴(𝑛𝑒𝑤-𝑆𝑅)𝑚 − [𝐴𝑀𝐴(𝑛𝑒𝑤-𝑆𝑅)𝑚 ×  𝑃𝑟𝑜𝑏[(𝑇(𝐼+1)𝑚 − 𝑇(𝐼)𝑚) > 𝑇(𝑀𝐴𝑋)𝑚]]  
Alternatively, 𝑬𝑴𝑨(𝑺𝑹)𝒎 = 𝑨𝑴𝑨(𝒏𝒆𝒘-𝑺𝑹)𝒎 − [𝑨𝑴𝑨(𝒏𝒆𝒘-𝑺𝑹)𝒎 ×  𝑫𝑵𝑬𝒎]   (24) 
Suppose a patient has to consume 3 medicines in a day, i.e., M=3 
Dosing regimen for 1st medicine (m1) is 
𝑁𝑅𝑚1 = 2; λm1 =
𝑁𝑅𝑚1
24
= 0.083; 
𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 = 12ℎ𝑟𝑠; 𝑆𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 12; 𝐿𝑎𝑟𝑔𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 𝑁𝑅𝑚1 × 𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 
Dosing regimen for 2nd medicine (m2) is 
𝑁𝑅𝑚2 = 3; λm2 =
𝑁𝑅𝑚2
24
= 0.125  
𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 = 6ℎ𝑟𝑠; 𝑆𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 6 ; 𝐿𝑎𝑟𝑔𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 𝑁𝑅𝑚2 × 𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 
Dosing regimen for 3rd medicine (m3) is 
𝑁𝑅𝑚3 = 4; λm3 =
𝑁𝑅𝑚3
24
= 0.167  
𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 = 5ℎ𝑟𝑠; 𝑆𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 5 ; 𝐿𝑎𝑟𝑔𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 𝑁𝑅𝑚3 × 𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 
 77 
Overall EMAM due to all three medicines will be a weighted average of EMAm1, EMAm2 and 
EMAm3. Where weights are determined based on primary and secondary medicines. We consider 
following three scenarios. 
Scenario 1: All 3 medicines are primary. 
𝑬𝑴𝑨(𝑺𝑹)𝑴 =
𝟏
𝟑
× 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟏 +
𝟏
𝟑
× 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟐 +
𝟏
𝟑
× 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟑   (25) 
Scenario 2: Medicine 1st is primary, and 2nd and 3rd are secondary. 
𝑬𝑴𝑨(𝑺𝑹)𝑴 =
𝟏
𝟐
× 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟏 +
𝟏
𝟒
× 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟐 +
𝟏
𝟒
× 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟑    (26) 
Scenario 3: Medicine 1st and 2nd are primary, and 3rd is secondary. 
𝑬𝑴𝑨(𝑺𝑹)𝑴 =
𝟐
𝟓
× 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟏 +
𝟐
𝟓
× 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟐 +
𝟏
𝟓
× 𝑬𝑴𝑨(𝑺𝑹)𝒎𝟑   (27) 
Therefore, 𝑬𝑴𝑨(𝑺𝑹)𝑴 = ∑ 𝐀𝐢
𝑴
𝒊=𝟏 𝑬𝑴𝑨(𝑺𝑹)𝒎𝒊      (28) 
Undesirable dose event in case of Simple and Persistent Reminders  
Undesirable dose event (UDE) 
𝑈𝐷𝐸𝐵𝐴𝑆𝐸(𝑚) =  𝑃𝑟𝑜𝑏[(𝑇(𝐼+1)𝑚 − 𝑇(𝐼)𝑚) < 𝑇(𝑀𝐼𝑁)𝑚] 
Or, 𝑼𝑫𝑬𝑩𝑨𝑺𝑬(𝒎) = (𝛌𝐦 × 𝒕𝒎)
𝒌𝒎 ×
𝒆−𝛌𝒎𝒕𝒎
𝒌!
 𝒇𝒐𝒓 𝒌𝒎 = 𝟐 𝒂𝒏𝒅 𝒕𝒎 = 𝑻(𝑴𝑰𝑵)𝒎   (29) 
𝑈𝐷𝐸𝑚 =  𝑃𝑟𝑜𝑏[(𝑇(𝐼+1)𝑚 − 𝑇(𝐼)𝑚) < 𝑇(𝑀𝐼𝑁)𝑚] 
𝑼𝑫𝑬𝒎 =
𝟏
𝟐
(𝛌𝐦 × 𝑻(𝑴𝑰𝑵)𝒎)
𝟐
× 𝒆−𝛌𝐦𝑻(𝑴𝑰𝑵)𝒎        (30) 
𝑈𝐷𝐸(𝑇𝑂𝑇𝐴𝐿)𝑚 =  𝑃𝑟𝑜𝑏[(𝑇(𝐼+1)𝑚 − 𝑇(𝐼)𝑚) < 𝑇(𝑀𝐼𝑁)𝑚] 
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𝑈𝐷𝐸(𝑇𝑂𝑇𝐴𝐿)𝑚 = [1 −
𝑇(𝑀𝐼𝑁)𝑚
24
𝑁𝑅𝑚
] × [(λm × 𝑡𝑚)
𝑘𝑚 ×
𝑒−λm𝑡𝑚
𝑘!
 𝑓𝑜𝑟 𝑘𝑚 = 2 𝑎𝑛𝑑 𝑡𝑚 = 𝑇(𝑀𝐼𝑁)𝑚]
+ [
𝑇(𝑀𝐼𝑁)𝑚
24
𝑁𝑅𝑚
× 𝑃(𝐷-𝑅)𝑚]
× [ (λm × 𝑡𝑚)
𝑘𝑚 ×
𝑒−λm𝑡𝑚
𝑘!
 𝑓𝑜𝑟 𝑘𝑚 = 1 𝑎𝑛𝑑 𝑡𝑚 = 𝑇(𝑀𝐼𝑁)𝑚] 
Therefore,  
𝑈𝐷𝐸(𝑇𝑂𝑇𝐴𝐿)𝑚 = [1 − λm𝑇(𝑀𝐼𝑁)𝑚] × [(λm × 𝑇(𝑀𝐼𝑁)𝑚)
2
×
𝑒−λm𝑇(𝑀𝐼𝑁)𝑚
2!
 ]
+ [λm𝑇(𝑀𝐼𝑁)𝑚 × 𝑃(𝐷-𝑅)𝑚] × [ (λm × 𝑇(𝑀𝐼𝑁)𝑚) × 𝑒
−λm𝑇(𝑀𝐼𝑁)𝑚 ] 
𝑼𝑫𝑬(𝑻𝒐𝒕𝒂𝒍)𝒎 = ∑ 𝑼𝑫𝑬𝐦𝐢
𝑴
𝒊=𝟏          (31) 
𝑼𝑫𝑬(𝑺𝑹)𝒎 = 𝑼𝑫𝑬(𝑻𝑶𝑻𝑨𝑳)𝒎 − 𝑼𝑫𝑬(𝑩𝑨𝑺𝑬)𝒎      (32) 
Scenario 2: Context-aware reminder - CAR 
Let us assume,  
 NRm is Number of prescribed doses in a day for mth medicine at TM intervals, where M is the 
number of medicines in a day 
 NPm is the number of reminders per missing dose for mth medicine 
 km is the event for mth medicine (km=0) 
 λm is the average arrival rate for mth medicine  
o where, λm =
NRm
24
 
 T(MAX)m is time (tm) observed for mth medicine 
 P(D-R)m is the Probability of taking dose due to reminder for mth medicine 
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 P(ND-R)m is the Probability of not taking dose due to reminder for mth medicine 
𝑃(𝑁𝐷-𝑅)𝑚 = 1 − 𝑃(𝐷-𝑅)𝑚 
 Qm is the number of reminders came in during last T(MAX)m for mth medicine 
𝑸𝒎 = 𝑵𝑷𝒎 ×
𝑻(𝐌𝐀𝐗)𝐦
𝟐𝟒
𝑵𝑹𝒎
        (33) 
 Probability of number of doses in the last T(MAX)m for mth medicine, i.e., Prob(NRm) is  
 𝐏𝐫𝐨𝐛(𝐍𝐑𝐦) = (𝐏(𝐍𝐃-𝐑)𝐦)
𝐐𝐦       (34) 
 Mean 𝝁𝒎 = 𝛌𝐦 × 𝒕𝒎         (35) 
 Probability of number of doses after the last reminder, i.e., Prob(km) is  
𝑷𝒓𝒐𝒃(𝒌𝒎) =
[𝝁𝒎
𝒌𝒎×𝒆−µ𝒎]
𝒌𝒎!
        (36) 
Multiplying equation 34 and 36 we get the probability that the gap between doses exceeded 
the maximum interdose-time, i.e., the dose is not effective (DNE). 
𝐷𝑁𝐸𝑚 = 𝑃𝑟𝑜𝑏[(𝑇(𝐼+1)𝑚 − 𝑇(𝐼)𝑚) > 𝑇(𝑀𝐴𝑋)𝑚] = [(P(ND-R)m)
Qm × 𝑃𝑟𝑜𝑏(𝑘𝑚)] 
𝑫𝑵𝑬𝒎 = 𝑷𝒓𝒐𝒃[(𝑻(𝑰+𝟏)𝒎 − 𝑻(𝑰)𝒎) > 𝑻(𝑴𝑨𝑿)𝒎] = [(𝐏(𝐍𝐃-𝐑)𝐦)
𝐐𝐦 ×
[𝝁𝒎
𝒌𝒎×𝒆−µ𝒎]
𝒌𝒎!
] (37) 
We Know, 𝐴𝑀𝐴𝑚 = 𝑁𝑚(𝑇𝑎𝑘𝑒𝑛)/𝑁𝑚(𝑃𝑟𝑒𝑠) 
𝑨𝑴𝑨(𝒏𝒆𝒘-𝑪𝑨𝑹)𝒎 = 𝑴𝑰𝑵[(𝑨𝑴𝑨𝒎 + 𝑷(𝑵𝑫-𝑹)𝒎 × 𝑸𝒎), 𝟏]    (38) 
𝐸𝑀𝐴(𝐶𝐴𝑅)𝑚 = 𝐴𝑀𝐴(𝑛𝑒𝑤-𝐶𝐴𝑅)𝑚 − [𝐴𝑀𝐴(𝑛𝑒𝑤-𝐶𝐴𝑅)𝑚 ×  𝑃𝑟𝑜𝑏[(𝑇(𝐼+1)𝑚 − 𝑇(𝐼)𝑚) > 𝑇(𝑀𝐴𝑋)𝑚]]  
Or, 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎 = 𝑨𝑴𝑨(𝒏𝒆𝒘-𝑪𝑨𝑹)𝒎 − [𝑨𝑴𝑨(𝒏𝒆𝒘-𝑪𝑨𝑹)𝒎 ×  𝑫𝑵𝑬𝒎]   (39) 
Suppose a patient has to consume 3 medicines in a day, i.e., M=3 and NPm=2 
Dosing regimen for 1st medicine (m1) is 
𝑁𝑅𝑚1 = 2; λm1 =
𝑁𝑅𝑚1
24
= 0.083; 
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𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 = 12ℎ𝑟𝑠; 𝑆𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 12; 𝐿𝑎𝑟𝑔𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 𝑁𝑅𝑚1 × 𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 
Dosing regimen for 2nd medicine (m2) is 
𝑁𝑅𝑚2 = 3; λm2 =
𝑁𝑅𝑚2
24
= 0.125  
𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 = 6ℎ𝑟𝑠; 𝑆𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 6 ; 𝐿𝑎𝑟𝑔𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 𝑁𝑅𝑚2 × 𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 
Dosing regimen for 3rd medicine (m3) is 
𝑁𝑅𝑚3 = 4; λm3 =
𝑁𝑅𝑚3
24
= 0.167  
𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 = 5ℎ𝑟𝑠; 𝑆𝑚𝑎𝑙𝑙𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 5 ; 𝐿𝑎𝑟𝑔𝑒𝑠𝑡 𝑇𝑀𝐴𝑋 = 𝑁𝑅𝑚3 × 𝐼𝑛𝑡𝑒𝑟𝑑𝑜𝑠𝑒 𝑡𝑖𝑚𝑒 
Overall EMA(CAR)M due to all three medicines will be a weighted average of EMA(CAR)m1, 
EMA(CAR)m2, and EMA(CAR)m3. Where weights are determined based on primary and secondary 
medicines. We consider following three scenarios. 
Scenario 1: All 3 medicines are primary. 
𝑬𝑴𝑨(𝑪𝑨𝑹)𝑴 =
𝟏
𝟑
× 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟏 +
𝟏
𝟑
× 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟐 +
𝟏
𝟑
× 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟑  (40) 
Scenario 2: Medicine 1st is primary, and 2nd and 3rd are secondary. 
𝑬𝑴𝑨(𝑪𝑨𝑹)𝑴 =
𝟏
𝟐
× 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟏 +
𝟏
𝟒
× 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟐 +
𝟏
𝟒
× 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟑   (41) 
Scenario 3: Medicine 1st and 2nd are primary, and 3rd is secondary. 
𝑬𝑴𝑨(𝑪𝑨𝑹)𝑴 =
𝟐
𝟓
× 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟏 +
𝟐
𝟓
× 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟐 +
𝟏
𝟓
× 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝟑   (42) 
Therefore, 𝑬𝑴𝑨(𝑪𝑨𝑹)𝑴 = ∑ 𝐀𝐢
𝑴
𝒊=𝟏 𝑬𝑴𝑨(𝑪𝑨𝑹)𝒎𝒊       (43) 
5.1.3 Model Validation 
Analytical models are the representations of mechanisms that govern natural phenomena that 
are not fully recognized, controlled or understood (Tedeschi 2006). They have become 
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indispensable tools via decision support systems for policy makers and researchers (Tedeschi 
2006). The main reason for modeling problems is it permits serious analysis and consideration of 
a problem, which has important financial, organizational and practical implications (Guerrero 
2010). However, certain techniques must be used to evaluate mathematical models for 
objectives, scope and assumptions, appropriateness or validation, and limitations. Essentially, the 
model should be appropriate for its intended purpose under the given conditions. 
For evaluation of smart interventions for effective medication adherence, our mathematical 
model is used to estimate dose-event (dose not effective, undesirable dose event), effective 
medication adherence (a single and multiple medications with multiple dosing regimen), and 
healthcare cost benefits of smart interventions. The model considers patients are living 
independently, their adherence behavior (0-100% medication adherence covering no-adherence, 
semi-adherence, and satisfactory adherence), and the type of illness (several chronic conditions), 
and prescribed self-administered medications.  The model allows the study of 
 Multiple chronic diseases including Diabetes, Hypertension (high blood pressure/BP), 
Hypercholesterolemia, and Chronic Heart Failure (CHF) 
 Independently living patients i.e. patients who are not living in a healthcare provider 
assisted environment 
 Healthcare cost including medical and drug cost 
 Simple and persistent reminders and context-aware reminders 
The model is appropriate (Tedeschi 2006) for studying adherence in chronic illnesses, where 
use of multiple medications extend over a period. The model can approximate the intervention 
and their cost. Therefore, the model is a valid and sound model and does what it is supposed to do 
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(Tedeschi 2006). Further, the three steps of model validation (Hamilton 1991): verification of the 
model, sensitivity analysis, and evaluation of the model, are performed below.  
The verification involved step by step checking of the model and debugging where one or 
more changes in inputs could lead to unacceptable output (Hamilton 1991; Tedeschi 2006). 
Further, the model was calibrated using values from other studies (Gibson et al. 2010; Roebuck et 
al. 2011; Sokol et al. 2005). The model builds upon prior models, and other studies also support 
the results obtained from this model. The model is validated by testing for many known cases to 
verify its functioning. Further, the causal relationships of medication adherence with medical cost, 
drug cost, and the intervention cost for multiple chronic conditions were utilized (Sokol et al. 
2005). All relationships in the model are verified, and known relationships were utilized for 
deriving additional relationships. 
The sensitivity analysis was performed to test the behavior of every equation in the model 
(Hamilton 1991). There are several ways to perform sensitivity analysis for mathematical models 
(Christopher Frey and Patil 2002). We focused on the nominal range sensitivity, which works 
well for models where there are no significant interactions among input values and the ranges of 
plausible values can be defined (using one’s judgment or from the literature). For our model, we 
broadly defined the ranges of all input values, obtained from other studies and expanded even 
further to cover more extreme cases. The analysis included combining several input values and 
measuring outputs for these combinations of inputs. The results section of this document presents 
the outcome of this analysis. It also helps in answering “what-if” questions such as “what if the 
patient does not consume the dose within the prescribed interval” or “what if patient consumed 
the dose one hour before or after the dose is due” or “what if an intervention stopped working”.  
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The evaluation of model was done to test the adequacy (or robustness) of the model based on 
precision and accuracy of results (Hamilton 1991; Tedeschi 2006). The model is precise as it 
produces values that are close to one another in multiple iterations. The accuracy of model is on 
(a) known relationships and (b) calibration of results for decision making. To measure accuracy 
further, we tested our model on input data and results from (Gibson et al. 2010; Roebuck et al. 
2011; Sokol et al. 2005). We further evaluated our model by computing the savings due to 
improved adherence under the all-disease cost of medications (Sokol et al. 2005). These values 
are in close agreement, so our results on effective medication adherence, undesirable dose event, 
and healthcare cost are validated using published data, while other results on smart interventions 
are extrapolated based on known relationships and available data from multiple studies.  
 Several assumptions (see section 5.1.1) were made to keep the analytical model tractable and 
reasonably accurate. In future work, these assumptions may be relaxed. 
The model can estimate the savings due to the improved effective medication adherence, the 
cost of various interventions, and the overall budget for various interventions. For a given 
improvement, knowing when an intervention is cost effective for a given condition can help an 
insurance company and/or employer in allocating healthcare resources. The analytical model, 
implemented in Excel (Guerrero 2010) and included in Appendix (A2), can be used to derive 
effective medication adherence for different dosing events, estimate savings due to improved 
medication adherence, and evaluate effective medication adherence for multiple medications.  
5.1.4 Limitations 
The model is primarily designed to address medication adherence in independent living, and 
will need extensions before its use in other more controlled environments such as assisted living 
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and hospitals. The model is designed to provide results with reasonable complexity, and in some 
cases, more refined results may be obtained by developing more complex models. 
Section 5.2 Empirical 
To see the validity of the proposed conceptual artifact domain experts (healthcare providers 
and health IT experts) have evaluated the artifact by comparing the health IT artifact with 
existing simple interventions. The evaluation of conceptual artifact is based on research design 
adapted from Parsons and Wand (Parsons and Wand 2008). The artifact evaluation protocol is 
available in Appendix (A1). After discussing the dissertation research with IRB, the application 
was submitted as non-human subject research to IRB for approval. Appendix (A1) includes the 
outcome letter of approval. 
We have focused explicitly on the experts' reasoning about their preferences between the 
existing and our smart interventions, and on relating that reasoning to the proposed health IT 
artifact. The evaluation will provide the insights for interventions preferred by experts. 
5.2.1 Participants and Task 
Domain experts consisted of six healthcare provider and six health IT experts. More 
specifically, healthcare providers are the physicians with extensive experience in advising and 
monitoring patients with chronic conditions prescribed self-administered medications. The three 
categories of health IT experts includes (1) two researchers in information systems with research 
and/or practical experience in medication adherence research, (2) two researchers in information 
systems with research and/or practical experience in health IT research, and (3) two health IT 
experts with extensive experience in healthcare system modeling and development. Health IT 
experts from information systems were chosen because of their familiarity with the medication 
adherence and health IT research and expected to be sufficiently motivated to provide thoughtful 
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responses. Also, modeling experts were chosen because they were expected to have relevant 
practical experience with the reasoning that takes place when developing a health IT system. 
Participants were asked to follow the instructions in Appendix A1 to compare Artifact1 and 
Artifact2 in Table 1 of the appendix (A1). The objectives for comparison were to: 
1. Focus participant’s attention on the differences in Artifact1 and Artifact2,  
2. Ask participants to formulate questions that could be asked to clarify the reasons why the 
differences arose,  
3. Observe which of the two artifact is considered more useful and realistic by the 
participants based on their domain experience,  
4. Observe which of the two artifacts is considered more reliable by the domain experts,  
5. Focus on participants reasoning for which artifact leads to overdose or over medication. 
Participants were not informed about the rules used to develop Artifact2. 
5.2.2 Analysis of Simple vs. Smart Intervention 
As discussed in the development section, following are the major differences between 
Artifact1 (Simple Intervention) and Artifact2 (Smart Intervention): 
1. Wireless Medication Box is used as an additional support for dose dispensing, and dispensing 
and consumption information of dose in Artifact2 as compared to Artifact1 
2. Analysis of consumption is done by Medication Management Server component of Artifact2.  
3. Medication Management Server in Artifact2 helps in providing context-aware reminders 
leading to smart interventions. 
4. Advice/scheduling support is available by a healthcare provider. 
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Participant 
(Healthcare 
provider-
HCP; 
Health IT 
Experts –
HITE) 
What 
differences can 
be identified 
between the 
two models? 
What 
questions 
could be 
asked to 
clarify the 
reasons for 
these 
differences? 
Which of the 
two might be 
more useful 
or realistic 
based on 
your general 
knowledge of 
the domain?  
Which one of 
these is more 
reliable or 
less likely to 
fail? 
Which one of 
these will lead 
to 
overdose/over 
medication? 
HCP 1  2nd is smarter, 
assuming the 
patient 
takes/swallows 
the pill. 
 2nd is less 
annoying – user 
friendly. 
 1st is More 
mechanical, 
repetitive. 
 Tell me 
more details of 
WMB: Is it 
portable? 
 Does is it 
have an alarm 
to get 
attention? 
 What 
happens if one 
misses the 
dose? 
 2nd will be 
more useful if 
above 
features 
added. 
 Second will 
be more 
reliable as 
long as the 
patient is 
honestly 
taking pills. 
 First – as it 
keeps sending 
reminders even 
when the 
patient has 
taken 
medicines. 
HCP 2  Model 2 has 
an additional 
component 
(WMB) which 
allow 
intelligence to 
be incorporated 
in the design 
leading to 
contextual 
awareness of 
“what” 
happened 
versus “when” 
it happened. 
Related to 
WMB 
 Is it 
pill/liquid 
based meds 
 Sensors in 
WMB 
sensitive to 
time alone or 
can patient 
open it 
anytime. 
 Model 2 
has additional 
layers of 
information. 
However, it 
limits the 
type of 
patients who 
can benefit; 
namely: 
taking solid 
pills, having a 
specific 
frequency 
(chronic 
medicines). 
 Reliability 
will depend 
on the 
healthcare 
“end” on how 
compatible it 
is on their 
side. 
 On the 
patient side 
model 2, is 
better than 1 
as it gives 
information 
and reminders 
from the 
nurse. 
 Overdosing 
is possible with 
Table/model 1. 
HCP 3  The second 
model involves 
the addition of a 
wireless 
medication box 
and active 
scheduling with 
the healthcare 
provider. 
 The 
additional 
steps could 
perhaps help 
dispense the 
appropriate 
dose and 
schedule of 
medications 
and avoid 
inappropriate 
dosing of 
medications. 
 The second 
model is 
probably 
more useful. 
 The second 
model is 
probably less 
likely to fail, 
but no system 
is perfect. 
 First model. 
HCP 4  Wireless 
medication box 
in model 2 is 
present, 
 Precise dose 
dispensing is 
important. 
 Dose 
schedule could 
 Model 2  Model 2  Model 1 
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 Context-
aware 
reminders and 
analysis of 
consumption 
between MMS 
and wireless 
network. 
 Advice 
scheduling 
between MMA 
and healthcare 
provider. 
be altered 
depending 
upon the 
response of 
medication. 
 In the case of 
sub dosing or 
overdosing, 
analysis of 
consumption 
and context-
aware 
reminders will 
be of immense 
help. 
HCP 5  Model 2 adds 
a wireless 
medication-
dispensing 
device and  
 Provides for 
analysis and 
sharing of 
dispensing and 
consumption 
information 
with the 
healthcare 
provider. 
 Don't you 
think that for 
the 
independent-
minded and 
the health-
conscious 
people, the 
fact that there 
would be too 
much 
involvement 
and reminders 
with pill taking 
with model 2-
may be off-
putting? 
 Model 2  Model 2  Both are 
unlikely to lead 
to 
overmedication
. 
HCP 6  In addition to 
going through 
compliance and 
patterns of use 
Artifact 2, has 
advice on 
scheduling & 
WMB; 
dispensing and 
consumption 
information. 
*patient 
symptom 
improvement 
could be added 
 Will it 
increase 
adherence/com
pliance and 
better outcome 
of treatment? 
 useful 
Artifact 2 
 Realistic 
Artifact 1 
because of 
less time 
consumption. 
 Artifact 2 is 
more reliable, 
& less likely 
to fail 
 Artifact 1 
will lead to 
overdose 
because no 
feedback on 
scheduling. 
HITE 1  MMS needs 
to be “Smart”, 
i.e., needs to 
have more 
processing 
capability to be 
able to do the 
 How do you 
decide that 
useful input 
has been done?  
 What is the 
difference 
between the 
MMS of 
 If the 
system can be 
designed to 
be foolproof 
or close to 
foolproof, 
then Model 2, 
(utilizing 
 Model 1: If 
the adherence 
is monitored 
by the 
doctor/nurse/c
aregiver. 
 Model 2: If 
technology 
 Model 2: If 
technology is 
not 
designed/imple
mented 
properly. 
 Model 1: If 
patient/caregiv
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context-aware 
analysis. 
 Artifact2 is 
heavily reliant 
on good input 
data, i.e., should 
not become a 
case of garbage 
data in garbage 
data out. 
Model 1 & 
Model 2? 
technology) 
would be 
more useful. 
can be made 
reliable 
enough 
(WMB/MMS) 
er are not 
careful. 
HITE 2  WMB - 
wireless 
medication box 
has been 
introduced for 
dispensing the 
dose.  
 Dispensing 
and 
consumption 
information 
have been 
stored for 
further analysis.  
 A context-
aware reminder 
has been added.  
 Healthcare 
provider can 
provide dose 
scheduling 
advice through 
MMA. 
 How 
woulddd these 
additional 
steps 
contribute 
towards the 
speedy 
recovery of the 
patient?  
 How the 
information 
being stored 
would help in 
preventive 
care? 
 diagram 2  diagram 2  diagram 1 
HITE 3  Advice 
scheduling 
 WMB, plus 
connections 
 Context-
aware 
reminders 
 Analysis of 
consumption  
 “Simple” vs. 
“Smart.” 
 What is the 
connection 
between 
contextual 
reminders and 
the patient? 
 Is the MMA 
still necessary 
with the 
WMB? 
 Model 1 
seems more 
practical 
 Model 2 
has potential 
to be more 
effective but 
may cost 
more to 
implement 
 More likely 
Model 2 
 More likely 
Model 1 
HITE 4  Smart 
Intervention is 
contexted. 
 Smart 
intervention 
analyzes the 
consumption 
information and 
provides 
updated 
dispensing info. 
 What does 
context-
awareness 
mean? What 
factors are 
considered? 
 Why there is 
a separate 
entity (WMB) 
for the 
feedback 
 Both are 
applicable 
solutions, 
based on my 
experience 
with IT 
solutions. 
 Second 
model 
(Smart) 
 Simple 
intervention 
Model 1. 
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provision? 
(Separate from 
MMA). 
HITE 5  Model 1 
provides 
interaction 
between the 
patient and the 
provider based 
on simple 
information 
exchange,  
 while under 
model 2, the 
intervention is 
enhanced by 
using more 
contextual and 
personalized 
information 
based on dose 
assumption 
information 
 Functionality 
 Usability 
 The degree 
of clinical 
decision 
support 
 The success 
of IT 
implementati
on or 
adoption 
depends on 
many factors. 
By assuming, 
that other 
factors of the 
two models 
are same, and 
the patient 
really has the 
capability to 
interact 
correctly with 
the system, 
generally 
model 2 will 
be useful. 
 A smarter 
solution more 
helps the 
process of 
medical 
intervention. 
 The simpler 
solution 
model 1 
would be 
more reliable. 
 Model 2 
integrates 
more 
information 
together and 
supports a 
higher level 
of clinical 
decision 
support, but it 
is more 
fragile 
 Model 1 may 
lead to 
overdose as 
there is no 
reminder based 
on 
personalized 
dose and 
consumption 
analysis. 
HITE 6  The second 
one uses 
context-aware 
reminders. 
 The second 
one includes the 
wireless 
medication box, 
which can trace 
patients' 
medication-
taking behavior 
more objective 
than self-report. 
 The mobile 
application also 
provides 
scheduling 
advice in the 
second model. 
 How to 
guarantee the 
medication-
taking 
information is 
accurate and 
reliable? 
 Which kind 
of reminder 
would be more 
effective in 
changing 
patients' 
behavior?  
 Normal 
reminder or 
context-aware 
reminder? 
 The second 
one will be 
more useful. 
 I think more 
simple means 
more stable. 
Thus, I think 
the first one is 
less likely to 
fail. 
 I think both 
of them should 
have a fairly 
low possibility 
of overdose, 
but the second 
one may have a 
higher 
possibility of 
taking 
medication not 
at the 
prescribed 
time. 
Table 8a. Participants feedback on comparison of artifact1 and artifact2 
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After analyzing the response of the participants recorded in Table 8a, all of the 12 
participants have identified these differences in the two artifacts. However, the clarification 
questions for the differences varies among participants. Table 8b categorizes the different types 
of questions, corresponding participants and identifying the question as functional or technical 
(Artifact2). Functional or technical identification will be helpful in analyzing and improving the 
artifact further for future research. 
Clarification question category Participant Functional versus 
Technical 
Category1: Details of WMB such as 
portability, sensitivity, types of medicines 
supported, will it increase adherence, 
confirmation of medication consumption 
HCP1, HCP2, HCP5, 
HCP6, HITE2, HITE6 
Functional 
Category2: Use of two separate entities WMB 
and MMA 
HCP3, HITE2, HITE3, 
HITE4 
Functional 
Category3: Too much involvement and 
reminders might be cumbersome for the 
patient.  
HCP5 Technical 
Category4: Connection between context-
aware reminder and patient, and analysis of 
consumption and context-aware reminder? 
HCP4, HITE4, HITE6 Functional 
Category5: Difference between MMS of 
Artifact1 and Artifact2 
HITE1, HITE5, HITE6 Technical 
Table 8b. Categorizing clarification questions 
While developing the artifact we came across same types of questions and the developed 
artifact answers all these questions. For example, all the details of WMB are considered while 
using it as one of the components. WMB and MMA both are required because WMB is used by 
patient and provides dosing consumption information to MMS. On the other hand, MMA 
provides an interface between the patient, healthcare provider, and MMS. Similarly questions in 
Category 4 and Category 5 addressed in the development section above. The concern of 
participant HCP5 about the artifact being cumbersome for the patient is important concern. 
However, the system is not as cumbersome as it seems to be. Patient, as well as healthcare 
provider, will interact with the MMA. MMA is a simple app to provide three-way interaction 
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between patient, healthcare provider and MMS. All the complexity is in MMS for making 
intelligent decisions and generating smart interventions and providing the smart intervention in 
the form of an informed message to the patient. This further reduces the complexity at the 
patient’s point of contact. Since MEMA comprises of functional and technical components and 
the clarification questions falls in both categories. It inclines the development process with the 
solution to real world problem scenario.  
Table 8c summarizes how 12 participants categorize Artifact1 and Artifact2 based on which 
model is useful, realistic, reliable or less likely to fail and lead to overdose/over medication.  
Model Artifact1 Artifact2 
Useful HITE4 HCP1, HCP2, HCP3, HCP4, 
HCP5, HCP6, HITE1, HITE2, 
HITE3, HITE4, HITE5, HITE6 
Realistic HCP6, HITE3, HITE4 HCP1, HCP2, HCP3, HCP4, 
HCP5, HITE1, HITE2, HITE4, 
HITE5 
Reliable or less likely to fail HITE5, HITE6 HCP1, HCP2(patient side), 
HCP3, HCP4, HCP5, HCP6, 
HITE1, HITE2, HITE3, HITE4  
Lead to overdose/over 
medication 
HCP1, HCP2, HCP3, HCP4, 
HCP6, HITE1, HITE2, HITE3, 
HITE4, HITE5 
HITE1, HITE6 
Table 8c. Categorizing artifact1 and artifact2 
As we can see from Table 8c, all the 12 participants identified Artifact2 (smart intervention) 
useful as compared to Artifact1. However, participant HITE4 says “Both are applicable 
solutions, based on my experience with IT solutions.” Moreover, for the same reason, HITE4 
identifies Artifact1 and Artifact2 to be realistic too. Also, participant HITE3 and HCP6 
categorizes Artifact1 (simple intervention) to be realistic. Participant HCP6 says “realistic 
Artifact 1 because of less time consumption.” All participants except HITE5 and HITE6 
categorizes model3 to be reliable or less likely to fail. However, participant HCP2 says 
“Reliability will depend on the healthcare “end” on how compatible it is on their side. On the 
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patient side model, 2 is better than 1 as it gives information and reminders from nurse”. It shows 
that participant is observing the involvement of healthcare provider and compatibility with 
technology for the reliability of the system.  
The decision for the reliability of a model by participant HITE1 bases on the argument 
“Model 1: If the adherence is monitored by the doctor/nurse/caregiver.  Model 2: If technology 
can be made reliable enough (WMB/MMS)”. Since we have discussed in development section 
that in Artifact1 adherence is monitored by the healthcare provider at the end of the prescribed 
dosing regimen not during the prescribed dosing regimen, so we have categorized the response 
of HITE1 as Artifact2 to be reliable keeping in mind that technology (WMB/MMS) is reliable. 
However, as no system is perfect so we would like to identify the limitation of our system 
here that if the wireless network is not working then WMB and MMS will not be able to interact, 
and the technology will not be reliable at that point of time. All the participants except HITE1 
and HITE6 have identified Artifact1 leading to overdose/over medication. Participant HITE1 
says “Model 2: If technology is not designed/implemented properly. Model 1: If 
patient/caregiver are not careful.” It relates to the same concern HITE1 has with the reliability of 
the system.  
So we can see that the integration of technology plays a crucial role in the effectiveness of 
the smart intervention. On the other hand, participant HITE6, mentions that “I think both of them 
should have a fairly low possibility of overdose, but the second one may have a higher 
possibility of taking medication, not at the prescribed time.” However, this reasoning does not 
align with the difference participant HITE6 mentioned between Artifact1 and Artifact2 in Table 
8a “The second one uses context-aware reminders. The second one includes the wireless 
medication box, which can trace patients' medication-taking behavior more objective than self-
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report. The mobile application also provides scheduling advice in the second model.” On the 
other hand, participant HCP5 mentions that “both unlikely to lead to overmedication.”  
The evaluation of smart intervention (Artifact2) with simple intervention (Artifact1) by 
domain experts is insightful in identifying that smart intervention seems to be a better 
intervention for improving the effectiveness of medication adherence. It is further verified by the 
analysis presented in Table 8a, 8b, and 8c as well as from the analysis description. However, as 
mentioned above smart intervention can be made more robust after addressing some of the 
concerns of healthcare providers and health IT experts related to the techniques and reliability of 
the system. 
Section 5.3 Results 
Using the analytical model, we derived several results for the impact of patterns of 
medication of adherence on effective medication adherence; compared effective medication 
adherence without any intervention, with simple and persistent reminders, and context-aware 
reminders for single medication multiple doses as well as multiple medications multiple doses. 
Also, we compared undesirable dose event for different scenarios. Last but not the least we have 
derived and compared the healthcare cost savings due to context-aware reminders, and 
healthcare cost saving due to simple and persistent reminders with healthcare cost when the 
patient was nonadherent. 
5.3.1 Patterns of Adherence 
To show the impact of the pattern, we take an example of three patients with different 
average levels and patterns of medication adherence. Table 9 shows the results, where the patient 
3 can achieve satisfactory effective adherence by having a highly desirable pattern. 
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 Patient 1 Patient 2 Patient 3 
Doses consumed 100% 90% 80% 
Pattern Lot of variations 
(20% probability 
of exceeding 
maximum 
interdose-time) 
Some variations (10% 
probability of 
exceeding maximum 
interdose-time) 
(0% probability of 
exceeding maximum 
interdose-time) 
Average medication 
adherence 
100% 90% 80% 
Effective medication 
adherence 
80% 80% 80% 
Comment Variations resulted 
in lower effective 
adherence 
Variations reduced 
effective adherence 
The best pattern leads to 
satisfactory adherence 
Table 9. Different adherence and patterns 
The patterns of adherence are studied based on Uniform and Poisson probability 
distributions. The results of both the distributions are used to confirm the effectiveness of 
medication over a particular interval of time.  For example, a patient is prescribed 3 doses in a 
day for 30 days. However, the patient takes less than prescribed doses for 5 days and for rest of 
the 25 days he tries to catch-up before doctor’s appointment. Alternatively, the patient takes less 
than prescribed doses for 10 days and again uses catch-up for 20 days. Here, the average rate of 
adherence is important, and the different patterns of adherence could make a difference. While 
calculating effective adherence we focused on the average probability of ideal timing and catch-
up timing. 
We considered both Uniform and Poisson distribution to study adherence. As shown in 
Figure 27, the differences are not huge, but we felt that Poisson will represent more variance and 
also there is evidence that medication consumption by people is closer to Poisson (Knafl et al. 
2004). So for rest of the results, we used Poisson distribution. 
Next, we study three different patterns of adherence. The average value was 100% as the 
patients consumed all doses using different patterns. In Random, every dose followed a random 
timing. One of the catch-up patterns involved a patient going easy on doses in the first 5 days (2 
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doses as opposed to 3/day) and then did catch up for the next 25 days, while the other catch-up 
pattern involved the same for 10 days of easy going and then catch up on 20 days. The effective 
medication adherence is present in all three patterns with Random showing the worst Effective 
Medication Adherence as compared to other catch up patterns. This is shown in the Figure 28. 
More flexible dose regimen (by using higher maximum interdose-time) leads to better Effective 
Medication Adherence.   
Next, we derive the probabilities of multi-dosing by the patients within the minimum 
interdose-time. The probability of 2 doses was higher than 3 or 4 doses as expected in Figure 29.  
 
Figure 27. Distributions for studying patterns of adherence 
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Figure 28.  The impact of maximum interdose-time on effective adherence 
 
 
Figure 29. The probability of multi-dosing 
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Next, we study three different levels of average adherence and their resulting Effective 
Medication Adherence as shown in Figure 30. As before, the effective medication adherence is 
higher as the maximum interdose-time increased. 
 
Figure 30. Effective adherence for different average values 
 
5.3.2 Effective Medication Adherence for Single Medication 
To validate the model, each of the equations for EMA is evaluated for a range of parameter 
values and the computed results are compared and analyzed to study the varied patterns of EMA. 
The patterns are compared and analyzed for different levels of medication adherence and 
probabilities of dose consumption due to reminders (PD-R). The levels of the number of 
reminders per missing dose (NP) are also varied to analyze the patterns of adherence in case of 
context-aware reminders (CAR). The results shown in the Figures 31, 32 and 33 are graphs 
plotted between TMAX in hours (Horizontal axis) versus EMA (Vertical Axis); and the plane 
represents the comparison between different scenarios as mentioned in the respective graphs. 
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Figures 31 and 32 show the comparison of no reminders (NR), simple and persistent 
reminders (SR) and context-aware reminders (CAR) for average medication adherence (AMA) 
of 100% and 80% respectively. From the graphs of Figures 31 and 32, we can see that the 
patterns of adherence are best in the case of CAR when the probability of taking dose due to the 
reminder (PD-R) is higher (85%-100%).  
Figure 31a shows EMA of a person when he/she is 100% adherent to medication for NR, SR, 
and CAR (with 1, 2, 3 and 4 persistent reminders). Also, the person follows the reminders only 
20% of the times. In the case of NR, the EMANR is in the range of 63%-86%. On the other hand, 
for SRs, EMASR ranges from 64%-87%.  In case of CARs, EMACAR ranges from 70%-91% 
(NP=1); 76%-94% (NP=2); 81%-96% (NP=3); 85%-98% (NP=4).  
 
Figure 31a 
 99 
 
Figure 31b 
 
Figure 31c 
Figure 31. Comparing EMA for NR, SR and CAR (AMA=100%) 
From Figure 31a, we can conclude that increase in context and persistence of reminders leads 
to the increase in EMA and improves the patterns of medication adherence. Figures 31b also 
reflects the same increase in EMA for various levels of reminders and persistence. On the other 
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hand, Figure 31c shows that if a person is 100% adherent to medication and follows all the 
reminders, then the EMA for SR and CAR is 100% as compared to EMA in the range of 63%-
86% in case of NR.   
Figure 32a shows the EMA of a person when he/she is 80% adherent to medication for NR, 
SR, and CAR (with 1, 2, 3 and 4 persistent reminders). Figure 32b represents that the person 
follows the reminders only 60% of the times. In the case of NR, the EMANR is in the range of 
44%-64%. On the other hand, for SRs, EMASR ranges from 54%-71%. In case of CARs, 
EMACAR ranges from 65%-77% (NP=1); 74%-80% (NP=2); 77%-79% (NP=3); 79%-80% 
(NP=4).  
 
Figure 32a 
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Figure 32b 
 
Figure 32c 
Figure 32. Comparing EMA for NR, SR and CAR (AMA=80%) 
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So we can conclude that increase in context and persistence of reminders leads to the 
increase in EMA and improves the patterns of effective medication adherence.  On the other 
hand, Figure 32c shows that if a person is 80% adherent to medication and follow all the 
reminders, then the EMA for SR and CAR is 80% as compared to EMA in the range of 44%-
64% in case of NR. 
Figure 33 shows the comparison of patterns of adherence for EMA with varied medication 
adherence, 2 persistent reminders and varied levels of dose consumption due to reminders.  
 
Figure 33a 
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Figure 33b 
 
Figure 33c 
Figure 33. EMA - (AMA=100% vs AMA80%); NP=2; PD-R= 80%, 60%, 20% 
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We can conclude from Figure 33a and 33b that at some point in time the patterns for CAR 
and SR coincide with each other for different PDR. For example, we can see that for NP=2, 
AMA=80% and PD-R=80% the pattern of adherence for simple reminders overlaps the pattern of 
adherence for context-aware reminders. Similarly, if the patient is 80% adherent to medication 
and takes the dose 80% of the time due to two persistent reminders, then the patient can achieve 
the same EMA as with 100% adherence to medications. 
We observed similar results from Figure 34 and Figure 35 as above after varying other input 
parameters such as dosing rate (λ), the number of reminders, and the probability of dose taking 
after a reminder. In Figure 34 and Figure 35, 3DD and 2DD represent 3 doses per day and 2 
doses per day respectively. 
 
 
Figure 34. Impact of Np on EMA for varying PDR 
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Figure 35. Impact of lambda on EMA with varying TMAX 
 
 
5.3.3 Undesirable dose event (UDE) 
Figure 36 shows the results for UDE. UDE can be a problem as higher UDE can lead to drug 
toxicity and/or adverse side effects, thus affecting the future adherence to medications. UDE is 
increased by simple and persistent reminders, and even when CAR is not highly reliable. 
 
Figure 36. Comparison of UDE for NR, SR, and CAR 
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Results show that the pattern of adherence has a significant impact on EMA. Also, higher 
levels of EMA can be achieved for more flexible medication regimen, such as those with higher 
values of maximum interdose-time. It is also possible for a patient with lower average adherence 
but a desirable pattern of adherence to have higher EMA than a patient with higher AMA and 
less desirable pattern. In the case of interventions, results show that (1) simple and persistent 
reminders can improve EMA, but lead to higher UDE in some cases; (2) context-aware 
reminders can improve EMA without increasing UDE.  
5.3.4 Effective Medication Adherence for Multiple Medication 
To evaluate the effective medication adherence for multiple medication (M) in a day, with 
multiple doses of each medicine, we evaluated EMA (SR) M and EMA (CAR) M. This will compare 
the EMA for simple and persistence reminders and context-aware reminders to see which 
intervention works better to improve EMA when patient is consuming multiple medications in a 
day. EMA is weighted average of EMA of individual medicines based on whether the medicine 
is primary or secondary. For the weighted average, the TMAX is considered in the range of 12hrs 
to 18hrs because during this time interval all 3 medicines have effective dosing times. However, 
individually the TMAX varies from 12hrs to 24hrs for NR1; 6hrs to 18hrs for NR2; and 5hrs to 
20hrs for NR3. 
Case 1: Patient is prescribed three independent medicines in a day with all three medicines 
having the same dosing rate. 
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Figure 37. Comparing EMA for SR and CAR (multiple medications) – Case1 
Case 2: Patient is prescribed three independent medicines in a day with two medicines 
having the same dosing rate and one with different dosing rate. 
 
Figure 38. Comparing EMA for SR and CAR (multiple medications) – Case2 
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Case 3: Patient is prescribed three independent medicines in a day with all three medicines 
having different dosing rate. 
 
Figure 39. Comparing EMA for SR and CAR (multiple medications) – Case3 
 
5.3.5 Healthcare cost  
Healthcare cost for nonadherent patients comprises of medical and drug cost. When a simple and 
persistent intervention is administered to a nonadherent patient, it helps in improving the 
medication adherence. However, due to additional undesirable dose event and cost of 
intervention, it increases the healthcare cost to some extent. Still the analysis shows that simple 
and persistent reminders bring the healthcare cost by approximately 15% to 20% (HCCOST_SR 
Scenario I and HCCOST-SR Scenario II in Figure 40). On the other hand, smart interventions 
improve the effectiveness of medication adherence as well as reduce the healthcare cost by 39% 
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(HCCOST-CAR Scenario I). Analysis of healthcare cost is conducted based on the data available 
in Sokol (2005) for the all-disease cost (medical and drug cost). 
 
Figure 40. Comparison of healthcare cost saving 
 
Section 5.4 Propositions 
5.4.1 Proposition 1 
Context-aware Reminders will always outperform Simple and Persistent Reminders in 
improving Effective Medication Adherence. 
EMA is higher for context-aware reminder (CAR) as compared to simple and persistent 
reminders (SR). 
Since equation 14 is 𝑬𝑴𝑨𝑪𝑨𝑹 = 𝑨𝑴𝑨𝑵𝑬𝑾-𝑪𝑨𝑹 × [𝟏 − ((𝑷𝑵𝑫-𝑹)
𝛌𝐓𝐌𝐀𝐗𝑵𝑷  ×  𝒆−𝛌𝐓𝐌𝐀𝐗)] 
And equation 9 is 𝐄𝐌𝐀𝐒𝐑 = 𝐀𝐌𝐀𝐍𝐄𝐖-𝐒𝐑 × (𝟏 − (𝑷𝑵𝑫-𝑹)
𝑸 [𝒆−𝛌𝐓𝐌𝐀𝐗])     
So for, 
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 [𝑨𝑴𝑨𝑵𝑬𝑾-𝑪𝑨𝑹 × [𝟏 − ((𝑷𝑵𝑫-𝑹)
𝛌𝐓𝐌𝐀𝐗𝑵𝑷  ×  𝒆−𝛌𝐓𝐌𝐀𝐗)]] > [𝐀𝐌𝐀𝐍𝐄𝐖-𝐒𝐑 × (𝟏 −
(𝑷𝑵𝑫-𝑹)
𝑸 [𝒆−𝛌𝐓𝐌𝐀𝐗])]  
Either, 𝑨𝑴𝑨𝑵𝑬𝑾-𝑪𝑨𝑹 > 𝐀𝐌𝐀𝐍𝐄𝐖-𝐒𝐑 
Or, 𝛌𝐓𝐌𝐀𝐗𝑵𝑷 > 𝑄  i.e.,  
𝐍𝐑
𝟐𝟒
𝐓𝐌𝐀𝐗𝑵𝑷 >
𝑻𝑴𝑨𝑿
𝟐𝟒
𝑵𝑹 
i.e., 𝑵𝑷 > 𝟏 which is true by definition. Therefore, 𝑬𝑴𝑨𝑪𝑨𝑹 > 𝑬𝑴𝑨𝑺𝑹 
Results represented in Figure 31, Figure 32, and Figure 33 aligns with analysis of Proposition 1. 
5.4.2 Proposition 2 
Simple and Persistent Reminders will generate more UDE than Context-aware Reminders. 
Equation 10 is: 
𝑼𝑫𝑬𝑻𝑶𝑻𝑨𝑳 = 𝑷𝒓𝒐𝒃((𝑻𝑰+𝟏 − 𝑻𝑰) < 𝑻𝑴𝑰𝑵) 
=  [𝟏 − 𝛌𝐓𝐌𝐈𝐍] × [(𝛌𝐓𝐌𝐈𝐍)
𝟐 ×
𝒆−𝛌𝐓𝐌𝐈𝐍
𝟐!
] +  𝛌𝐓𝐌𝐈𝐍 × 𝑷𝑫-𝑹 × [(𝛌𝐓𝐌𝐈𝐍) × 𝒆
−𝛌𝐓𝐌𝐈𝐍] 
Equation 15 is: 𝐏𝐫𝐨𝐛((𝐓𝐈+𝟏 − 𝐓𝐈) < 𝐓𝐌𝐈𝐍) = (𝛌𝐓𝐌𝐈𝐍)
𝟐 ×
𝐞−𝛌𝐓𝐌𝐈𝐍
𝟐!
  
Comparing equation 10 and equation 15, 
[𝟏 − 𝛌𝐓𝐌𝐈𝐍] × [(𝛌𝐓𝐌𝐈𝐍)
𝟐 ×
𝒆−𝛌𝐓𝐌𝐈𝐍
𝟐!
] +  𝛌𝐓𝐌𝐈𝐍 × 𝑷𝑫-𝑹 × [(𝛌𝐓𝐌𝐈𝐍) × 𝒆
−𝛌𝐓𝐌𝐈𝐍]
>  (𝛌𝐓𝐌𝐈𝐍)
𝟐 ×
𝐞−𝛌𝐓𝐌𝐈𝐍
𝟐!
 
OR,  [ 
(𝟏−𝛌𝐓𝐌𝐈𝐍)
𝟐
+ 𝑷𝑫-𝑹 ] >
𝟏
𝟐
 
OR,  [
𝟏
𝟐
−
𝛌𝐓𝐌𝐈𝐍
𝟐
+ 𝑷𝑫-𝑹 ] >
𝟏
𝟐
 
OR,  [𝑷𝑫-𝑹 −
𝛌𝐓𝐌𝐈𝐍
𝟐
] >
𝟏
𝟐
−
𝟏
𝟐
 
OR,  [𝑷𝑫-𝑹 −
𝛌𝐓𝐌𝐈𝐍
𝟐
] > 𝟎 
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Therefore, 𝑷𝑫-𝑹 >
𝛌𝐓𝐌𝐈𝐍
𝟐
  
For example, 𝛌 =
𝟑
𝟐𝟒
, 𝐓𝐌𝐈𝐍 = 𝟏-𝟒𝒉𝒓, 𝑻𝒉𝒆𝒏 𝑷𝑫-𝑹 >
𝟏
𝟒
 , 𝒊. 𝒆. , 𝟐𝟓% 𝒄𝒉𝒂𝒏𝒄𝒆𝒔 𝒐𝒇 𝒕𝒂𝒌𝒊𝒏𝒈 𝒎𝒆𝒅𝒊𝒄𝒂𝒕𝒊𝒐𝒏 𝒅𝒖𝒆 𝒕𝒐 𝒓𝒆𝒎𝒊𝒏𝒅𝒆𝒓𝒔. 
Results represented in Figure 36 where the undesirable dose event for 3 different scenarios is 
compared aligns with analysis of Proposition 2. 
5.4.3 Proposition 3 
The EMA will be minimum when the probability of consuming dose due to reminder is 
minimum and maximum interdose-time between doses is as prescribed. 
Using equation 9, we can derive the lowest value for EMA, i.e., EMAMIN for persistent 
reminders. 
𝐄𝐌𝐀𝐌𝐈𝐍-𝐒𝐑 = 𝐀𝐌𝐀𝐍𝐄𝐖 ×  (𝟏 − (𝑷𝑵𝑫-𝑹)
𝑸 [𝒆−𝛌𝐓𝐌𝐀𝐗])
= 𝐌𝐢𝐧[(𝐀𝐌𝐀 + (𝟏 − 𝐏𝐍𝐃-𝐑) × 𝛌𝐓𝐌𝐀𝐗), 𝟏] × (𝟏 − (𝑷𝑵𝑫-𝑹)
𝑸 [𝒆−𝛌𝐓𝐌𝐀𝐗]) 
The variables used in this equation are as follows: 
𝐀𝐌𝐀, 𝐏𝐍𝐃-𝐑, 𝛌𝐓𝐌𝐀𝐗 𝒂𝒏𝒅 𝑸 𝒘𝒉𝒆𝒓𝒆 𝑸 =  𝛌𝐓𝐌𝐀𝐗 
 For EMA to be minimum: 
i. It is desirable that (𝟏 − 𝐏𝐍𝐃-𝐑) × 𝛌𝐓𝐌𝐀𝐗 should be minimum, and  
ii. It is required that 𝟏 − (𝑷𝑵𝑫-𝑹)
𝑸 [𝒆−𝛌𝐓𝐌𝐀𝐗] = 𝟏 − (𝑷𝑵𝑫-𝑹)
𝛌𝐓𝐌𝐀𝐗  [𝒆−𝛌𝐓𝐌𝐀𝐗] = 𝟏 −
(
𝑷𝑵𝑫-𝑹
𝒆
)
𝛌𝐓𝐌𝐀𝐗
 is minimum.  
Alternatively, we can say (
𝑷𝑵𝑫-𝑹
𝒆
)
𝛌𝐓𝐌𝐀𝐗
 should be maximum. It implies, 𝐏𝐍𝐃-𝐑 should be 
maximum AND/OR 𝛌𝐓𝐌𝐀𝐗 should be close to zero. Using equation 14, we can derive the lowest 
value for EMA, i.e., EMAMIN for context-aware reminders. 
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𝑬𝑴𝑨𝑴𝑰𝑵-𝑪𝑨𝑹 = 𝑨𝑴𝑨𝑵𝑬𝑾 × (𝟏 − [(𝑷𝑵𝑫-𝑹)
𝛌𝐓𝐌𝐀𝐗  ]
𝑵𝑷
 × [ 𝒆−𝛌𝐓𝐌𝐀𝐗])
= 𝐌𝐢𝐧[(𝐀𝐌𝐀 + (𝟏 − 𝐏𝐍𝐃-𝐑)
𝐍𝐏)), 𝟏] × [𝟏 − ((𝑷𝑵𝑫-𝑹)
𝛌𝐓𝐌𝐀𝐗𝑵𝑷  ×  𝒆−𝛌𝐓𝐌𝐀𝐗)] 
Since equation 14 is 𝑬𝑴𝑨𝑪𝑨𝑹 = 𝑨𝑴𝑨𝑵𝑬𝑾 × [𝟏 − ((𝑷𝑵𝑫-𝑹)
𝛌𝐓𝐌𝐀𝐗𝑵𝑷  ×  𝒆−𝛌𝐓𝐌𝐀𝐗)] 
Moreover, equation 4 is 𝑬𝑴𝑨 = 𝑨𝑴𝑨 × (𝟏 − 𝑫𝑵𝑬) = 𝑨𝑴𝑨 × (𝟏 − 𝒆−𝛌𝐓𝐌𝐀𝐗)   
We know that, 𝑨𝑴𝑨𝑵𝑬𝑾 ≥ 𝑨𝑴𝑨. Using equation 14 and 4 we can say that following 
condition must be true, i.e.,  (𝑷𝑵𝑫-𝑹)
𝛌𝐓𝐌𝐀𝐗𝑵𝑷 < 𝟏 
⇒ 𝑆𝑖𝑛𝑐𝑒, 𝑷𝑵𝑫-𝑹 < 𝟏 𝑆𝑜 𝑓𝑜𝑙𝑙𝑜𝑤𝑖𝑛𝑔 𝑒𝑞𝑢𝑎𝑡𝑖𝑜𝑛 𝑚𝑢𝑠𝑡 𝑏𝑒 𝑡𝑟𝑢𝑒, 𝑖. 𝑒. , 𝛌𝐓𝐌𝐀𝐗𝑵𝑷 > 𝟏 
Now we know that λ is the average arrival rate, and TMAX varies from 8 hours to 16 
hours. Also, NP is always greater than 1 being the Number of reminders per missing dose 
event. It implies  𝛌𝐓𝐌𝐀𝐗𝑵𝑷 > 𝟏 holds true. Detailed analysis of results shown in Figure 31, 
Figure 32, and Figure 33 confirms with Proposition 3.  
5.4.4 Proposition 4  
The UDE is maximum when the minimum gap between doses is equal to or greater than 
the regular gap between medications. 
Evaluating equation 10 (UDE for simple and persistent reminders) for finding UDEMAX  
𝑼𝑫𝑬𝑻𝑶𝑻𝑨𝑳 = [𝟏 − 𝛌𝐓𝐌𝐈𝐍] × [(𝛌𝐓𝐌𝐈𝐍)
𝟐 ×
𝒆−𝛌𝐓𝐌𝐈𝐍
𝟐!
] + [𝛌𝐓𝐌𝐈𝐍 × 𝑷𝑫-𝑹 ]  × [(𝛌𝐓𝐌𝐈𝐍) ×
𝒆−𝛌𝐓𝐌𝐈𝐍]    
Since UDE is a probability, this can have a maximum value of 1. 
Let us consider following three parameters if the prescribed doses are 3 in an interval of 8 
hours: λ =
𝐍𝐑
24
         𝑇𝑀𝐼𝑁 = (𝑀𝑖𝑛, 𝑀𝑎𝑥)       𝑃𝐷-𝑅 = (0, … … .1) 
UDEMAX will be .368 when minimum gap between medications is equal to the regular gap 
between medications, i.e., when λ =
3
24
 , 𝑇𝑀𝐼𝑁 = 8,  𝑃𝐷-𝑅 = 1 
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It holds true for 2doses/day at 12hrs intervals as well as 4doses/day at 5 hrs interval. We can 
have higher value of UDE beyond the regular gap between medications, but [𝟏 − 𝛌𝐓𝐌𝐈𝐍] ×
[(𝛌𝐓𝐌𝐈𝐍)
𝟐 ×
𝒆−𝛌𝐓𝐌𝐈𝐍
𝟐!
] component (the probability of patient taking two doses when no reminder 
came) of UDE becomes negative too. After analyzing results represented in Figure 36, we can 
confirm the analysis of Proposition 4. 
5.4.5 Proposition 5 
The maximum healthcare savings due to context-aware reminders is always higher than 
simple persistent reminders when there are no failures. 
Since equation 16a is: 𝐇𝐂𝐂𝐎𝐒𝐓𝐍𝐀 = (𝐇𝐂𝐂𝐎𝐒𝐓-𝐏𝐀𝐒𝐓) × (𝟏. 𝟎𝟓)
𝐍      
Equation 16b is: 𝐇𝐂𝐂𝐎𝐒𝐓𝐒𝐑 = (𝐇𝐂𝐂𝐎𝐒𝐓-𝐏𝐀𝐒𝐓) × (𝟏. 𝟎𝟓)
𝐍 × (𝟏 + 𝐔𝐃𝐄𝐒𝐑) + 𝐈𝐍𝐓𝐕𝐍𝐂𝐎𝐒𝐓-𝐒𝐑  
Equation 16c is: 𝐇𝐂𝐂𝐎𝐒𝐓𝐂𝐀𝐑 = (𝐇𝐂𝐂𝐎𝐒𝐓-𝐏𝐀𝐒𝐓) × (𝟏. 𝟎𝟓)
𝐍 + 𝐈𝐍𝐓𝐕𝐍𝐂𝐎𝐒𝐓-𝐂𝐀𝐑     
Therefore, from equation 16b and 16c we can see that the healthcare cost due to simple 
persistent reminders includes the additional cost for UDE as compared to healthcare costs due to 
context-aware reminder. Also, the intervention cost (INTVNCOST) varies for context-aware 
reminders as compared to simple persistent reminders. Results represented in Figure 40 helps us 
in a detailed analysis of Proposition 5.  
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Chapter 6. Conclusion 
Improving the rate of medication adherence is a serious concern. Most of the studies on 
improving medication adherence focus on one or more interventions and measure average rate of 
medication adherence. Although the average rate of medication adherence is useful, we note that 
patients could achieve the same average medication adherence value with widely different 
consumption patterns including those where patients have not consumed any doses for several 
days and then taken multiple doses or doses that are more frequent. In this research, we focus on 
the idea that in addition to the average rate of medication adherence, the patterns of adherence 
and effective medication adherence should also be studied. These are more likely to be a better 
predictor of outcomes than average medication adherence alone. 
Using design science research (DSR) approach we have developed a model for smart 
interventions as health IT artifact. We have leveraged behavior change techniques (BCTs) based 
on behavior change theories to design smart intervention. Because of the need for real time 
requirements for the system, we are also focusing on hierarchical control system theory and 
reference model architecture (RMA). The benefit of using this design will be allowing an 
intervention to be administered dynamically on a need basis. A key distinction from existing 
systems is that the developed artifact leverages probabilistic measure instead of static schedule. 
We have developed a health IT artifact with intelligence and persistence for the reminders. 
Interventions that stimulate better adherence to essential medications even slightly may 
meaningfully improve public health (Friedman et al. 1996; Haynes et al. 2005). The uniqueness 
of our health IT artifact, termed MEMA, is that it does not create a schedule of administering the 
interventions but decides the next administration of the intervention dynamically. It creates a 
schedule of prescribed dosing events at the time of prescription and also registers actual dosing 
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event of the patient during prescription. A probable rate of effective medication adherence 
(EMA) generates at each dosing event of the patient and the prescribed dosing event. Based on 
the value of EMA, an appropriate type of intervention is chosen and scheduled either before or at 
the next dosing event for the patient. It may also happen that intervention is not deemed 
necessary for the next prescribed dosing event if the patient is 100% following the prescribed 
dosing regimen. The type of intervention denotes the priority we associate to the next scheduled 
intervention in maintaining the EMA above a specified threshold (depending on the type of care 
and therapy received).  It will consider the dosing frequency and time for a particular dosing 
regimen. In this way, the context-aware reminders provided by MEMA will not lead to the 
undesirable dose event (UDE).  
We have evaluated and validated the artifact using analytical model and empirically 
evaluated the effectiveness of the health IT artifact by having domain experts assess the simple 
and smart intervention. Two categories of domain experts considered are the healthcare provider 
and health IT experts. Focus is explicitly on the experts' reasoning about their preferences 
between the existing and our smart interventions, and on relating that reasoning to the proposed 
health IT artifact. This evaluation provides the insights for interventions preferred by experts. As 
discussed in section 5.2, domain experts prefer smart intervention as compared to simple 
intervention. There is one limitation of concern to the experts that is the reliability of the health 
IT system. Patient-provider concordance is also mentioned by some of the experts as one the 
factor for effectiveness of the smart intervention. The smart intervention is developed 
considering the patient-provider concordance during the medication therapy/persistence.  
The results have significant implication for the healthcare system and researchers studying 
medication adherence and interventions. The patterns of adherence will be useful in studying 
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effective medication adherence (EMA) for patients to improve medication adherence. Our results 
show that (1) simple interventions can improve the pattern of adherence and the average rate of 
medication adherence, but can also increase the probability of undesirable dose events 
sometimes; (2) smart interventions can improve both the pattern and average value of adherence 
without increasing the undesirable dose events.  
The results of our analysis have significant implications for healthcare providers, patients, 
insurance companies, and health IT researchers interested in improving healthcare delivery and 
outcomes. Higher levels of effective adherence can be achieved for more flexible medication 
regimen, such as those with higher values of maximum interdose-time. It is also possible for a 
patient with lower average adherence but a more desirable pattern of adherence to have higher 
effective medication adherence than a patient with higher average adherence with a less desirable 
pattern of adherence. Also, the smart intervention will work for patients who are willing and can 
take medication when reminded.  
Section 6.1 Research Questions and Discussion 
The design science research process followed in this research occurred in phases, and each 
phase was instrumental in arriving at the conclusions discussed herein. This research recognized 
the problem of nonadherence and the tremendous impact it has has upon financial and treatment 
outcomes, especially among chronic patients prescribed self-administered medications. The 
problem of nonadherence has been prevalent and very little progress in improving the rate of 
medication adherence has been achieved so far. The perspective this research carried during 
literature reviews to identify possible solutions to this problem was to revisit the fundamental 
question related to this problem i.e. what it meant to be nonadherent and the bearing it had on the 
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medication adherence. Analysis of this fundamental question provided greater insight into the 
effectiveness of medication adherence and arrived at the research problem. 
This research examined how patterns of medication adherence impact effective medication 
adherence (EMA)? The outcome of this examination was a measure of effective medication 
adherence (EMA) that could capture the effectiveness of medication adherence within the 
medication persistence. So far, measurements were for average medication adherence that one 
could arrive at only towards the end of medication persistence. Improving the rate of medication 
adherence needs interventions that are effective for the healthcare providers to administer and 
patients to follow. Based upon the measure of EMA, this research developed a health IT model 
for effective medication adherence that could allow the healthcare providers to administer smart 
interventions. The overall usefulness of smart interventions with results on improving effective 
medication adherence and reducing healthcare costs is validated.  
The guiding questions at various stages of DSR process are revisited to assess the knowledge 
gained at each stage: 
• Awareness of Problem: If interventions to medication nonadherence can improve 
medication adherence, why such interventions are not effective? Nonadherence is a 
multidimensional problem, and current measure of adherence does not support intervention 
within the period of medication persistence where it can be effectively intervened. 
• Suggestion: How can the effectiveness of interventions be improved? By enabling 
healthcare providers to assist patients in improving their medication adherence and adopting the 
use of smart interventions that are based on effective medication adherence and provide the 
ability to intervene when there is a need. EMA generates at the actual dose event and the 
prescribed dose events. 
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• Development: How closely does the new model represent the original model/design of the 
available interventions? The new model for MEMA is an enhancement to existing model and 
augments the existing design with real time intelligent decision system. 
• Evaluation: What are the limiting conditions for the effectiveness of interventions 
utilizing new model? Besides the theoretical limits to improving the effective medication 
adherence, there are practical limitations like developing a classification for the thresholds that 
EMA should never fall below or for accessing the impact on a specific prescription based on 
medicines administered. Development of classification for different medication regimen is an 
identified future research. 
• Conclusion: Do the smart interventions improve effectiveness of medication adherence? 
Health Behavior Change Theories indicate so, and validations using the sample data proved that 
smart interventions improve medication adherence overall and also improve the effectiveness of 
medication adherence. 
Section 6.2 Research Contribution 
6.2.1 Contribution to Information Systems 
Baskerville and Myers (2002) suggested that the “potential audience for IS field includes 
scholars in any field that is vitally concerned with the development, use, and application of 
information technology and systems” (p. 8). They have specifically mentioned this potential in 
medical fields (Baskerville and Myers 2002 pp. 8). The healthcare industry poses important 
social challenges and interesting research possibilities for researchers interested in the 
development and use of information systems and technologies (Agarwal et al. 2010; Chiasson 
and Davidson 2004; Romanow et al. 2012). We have leveraged the in-depth knowledge of an IS 
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researcher to influence healthcare practice (Agarwal et al. 2010) by increasing effectiveness of 
interventions, improving medication adherence and advancing the behavior change techniques. 
Without the use of information technology (IT), measuring medication adherence can be 
onerous, with feasibility and cost being barriers. Innovations in health IT utilizing the IS 
advancements can increase the feasibility of monitoring, accuracy, and widespread usage of 
medication adherence tools (Williams et al. 2014). Using IS/IT perspective and application of 
behavior change theories (behavior change techniques) we have developed an IT based smart 
intervention to address the multidimensional issue of medication adherence. Smart intervention 
helps in improving medication adherence which further helps in minimizing the healthcare cost, 
improving the healthcare quality and advancing behavior change techniques. 
This research contributes a health IT domain specific artifact to the DSR community. The 
artifact developed in this study solves a specific problem of low medication adherence among 
chronic patients prescribed self-administered medications. The artifact is made a general artifact 
(Iivari 2015) by using some of the requirements and design processes presented in this research. 
Finally, the research adds to the IS knowledge base by providing the theory based smart 
interventions based on BCTs and RMA for improving the medication adherence. 
6.2.2 Contribution to Health IT 
This research focuses on the effectiveness of medication adherence and the impact of 
medication behavior on the overall effectiveness of treatment outcome. Specifically, we propose 
that pattern of adherence along with average medication adherence is a better predictor of health 
outcomes. Effective medication adherence captures the context for smart interventions that helps 
increase the rate of medication adherence and lower the healthcare costs. Propositions 1 through 
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5 are validated design rules for the development of smart interventions and can be useful for 
future research related to medication adherence and development of new interventions.  
The developed model can be utilized to create, implement and evaluate health IT artifacts for 
health and wellness, and daily activity monitoring. Although our work can lead to numerous 
types of health IT artifacts and related interventions, here we briefly discuss two such examples.  
1. Health and wellness: The health IT artifact can be generalized for dieticians to create 
dietary charts for patients to track health and wellness. These dietary charts updatesare 
updated in the medication management server, and a copy is provided to patients. In this 
way, a three way interaction and adherence to the diet can be tracked and improved by 
providing smart interventions through the modified system.  
2. Daily activity monitoring: The health IT artifact for physiotherapists is used for assisting 
patients to manage pain and follow daily exercise routines. It administers Smart 
interventions by managing the interaction between medication management server 
(which will store the exercise schedule provided by physiotherapist and routine followed 
by patients), patient and physiotherapists. 
The theory based smart intervention improves medication behavior among nonadherent 
patients. The effect of smart interventions on medication behavior can enrich the knowledge base 
for Health Behavior Change Theories. New medication behaviors can be examined and can lead 
to further theory and behavior change techniques development. 
Section 6.3 Limitations and Future Research 
The current design has the limitation that patient should be willing to take medication as the 
interventions designed for prescribed self-administered medications. Regarding artifact 
evaluation, it can be further extended by conducting a field study where the modeled artifact can 
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be made accessible to patients and healthcare provider to use. It will help in empirical validation 
of the artifact. The ability of patients to interact with mobile devices and applications are studied 
in determining the effectiveness of interventions for medication adherence. This research is also 
cognizant that deciding the ‘Type of intervention’ requires extensive study of therapy regimens, 
medication behaviors, and medical conditions. It can become an active research topic. The future 
work can involve  
1. comparing patterns of adherence for different conditions: acute vs. chronic,  
2. comparing patterns of adherence for chronic conditions over long time,  
3. studying the patterns of people living alone vs. people living with a caregiver, and  
4. designing highly personalized context-aware interventions for patients based on pattern 
as well as average medication adherence and the patient's condition.  
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Appendices 
A1. Empirical evaluation form used by domain experts  
Instructions for Expert 
 
There are two artifacts (Table 1) and their respective specifications. These artifacts constitute 
the interventions for improving medication adherence among chronic disease patients.  Artifact1 
provides simple interventions/reminders to patients to take medications based on the prescription 
information provided by the healthcare professional and dosing information provided by the 
patient. Artifact2 provides smart interventions based on the prescription information provided by 
the healthcare professional and dosing information provided by the patient. Artifact2 includes 
some additional information, which is missing in Artifact1. So please examine Artifact1 and 
Artifact2 for improving medication adherence and answer the questions in Table 2.  
 
Note: We are aware of that Artifact2 is still partial and some information is missing. We ask 
that you base your responses on the interventions as presented. 
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Table 1 
 
 
Artifact1(Simple intervention) 
 
 
Artifact2(Smart Intervention) 
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Table 2 
Questions Response 
(1) What differences can be 
identified between the two 
artifacts? 
 
 
 
 
 
 
 
 
(2) What questions could be 
asked to clarify the 
reasons for these 
differences? 
 
 
 
 
 
 
 
 
 
 
(3) Which of the two might be 
more useful or realistic 
based on your general 
knowledge of the domain?  
 
 
 
 
 
 
 
 
 
 
 
(4) Which one of these is 
more reliable or less likely 
to fail? 
 
 
 
 
 
 
 
 
 
(5) Which one of these will 
lead to overdose/over 
medication? 
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IRB Outcome Letter for Non-Human Subject Research 
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A2 Analytical Model Implementation Using Excel 
A2.1 Effective Medication Adherence (EMA) for Single Medication, Multiple Doses 
Simple and Persistent Reminder 
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Context-aware Reminder 
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A2.2Effective Medication Adherence for Multiple Medication, Multiple Doses 
Simple and Persistent Reminder Vs Context-aware Reminder 
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A2.3 Undesirable Dose Event 
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A2.4 Healthcare cost 
Healthcare cost Nonadherent, Simple Intervention and Smart Intervention 
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A3 Theoretical Background 
A3.1 Factors reported affecting medication adherence (Meducation 2006) 
 
1. SOCIAL AND ECONOMIC DIMENSION 
• Limited English language proficiency 
• Low health literacy 
• Lack of family or social support network 
• Unstable living conditions; homelessness 
• Burdensome schedule 
• Limited access to healthcare facilities 
• Lack of healthcare insurance 
• Inability or difficulty accessing pharmacy 
• Medication cost 
• Cultural and lay beliefs about illness and treatment 
• Elder abuse 
2. HEALTHCARE SYSTEM DIMENSION 
• Provider-patient relationship 
• Provider communication skills  
• Disparity between the health beliefs of the healthcare provider and those of the patient 
• Lack of positive reinforcement from the healthcare provider 
• Weak capacity of the system to educate patients and provide follow-up 
• Lack of knowledge on adherence and of effective interventions for improving it 
• Patient information materials are written at too high literacy level 
• Restricted formularies; changing medications covered on formularies 
• High drug costs, copayments, or both 
• Poor access or missed appointments 
• Long wait times 
• Lack of continuity of care 
3. CONDITION-RELATED DIMENSION 
• Chronic conditions 
• Lack of symptoms 
• Severity of symptoms 
• Depression 
• Psychotic disorders 
• Mental retardation/developmental disability 
4. THERAPY-RELATED DIMENSION 
• Complexity of medication regimen (number of daily doses; number of concurrent medications) 
• Treatment requires mastery of certain techniques (injections, inhalers) 
• Duration of therapy 
• Frequent changes in medication regimen 
• Lack of immediate benefit of therapy 
• Medications with social stigma attached to use 
• Actual or perceived unpleasant side effects 
• Treatment interferes with lifestyle or requires significant behavioral changes 
5. PATIENT-RELATED DIMENSION 
Physical Factors 
• Visual impairment 
• Hearing impairment 
• Cognitive impairment 
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• Impaired mobility or dexterity 
• Swallowing problems 
Psychological/Behavioral Factors 
• Knowledge about disease 
• Perceived risk/susceptibility to disease 
• Understanding reason medication is needed 
• Expectations or attitudes toward treatment 
• Perceived benefit of treatment 
• Confidence in ability to follow treatment regimen 
• Motivation 
• Fear of possible adverse effects 
• Fear of dependence 
• Feeling stigmatized by the disease 
• Frustration with healthcare providers 
• Psychosocial stress, anxiety, anger 
• Alcohol or substance abuse 
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A3.2 Models and Concepts for Health Behavior Change 
(Revere and Dunbar 2001) 
Concept Definition Application 
Health Belief Model (Rosenstock et al. 1994): 
Perceived susceptibility 
One's opinion of chances of getting a 
condition 
Personalize risk based on a person's 
features or behavior. 
Perceived severity 
One's opinion of how serious a 
condition and its consequences are 
Specify consequences of the risk and 
the condition. 
Perceived benefits 
One's opinion of the efficacy of the 
advised action to reduce risk or 
seriousness of impact 
Define action to take; how, where, 
when; clarify the positive effects to be 
expected. 
Perceived barriers 
One's opinion of the tangible and 
psycho- logical costs of the action 
Identify and reduce barriers through 
reassurance, incentives, assistance. 
Cues to action Strategies to activate “readiness.” 
Provide how-to information, promote 
awareness, and provide reminders. 
Self-efficacy 
Confidence in one's ability to take 
action 
Provide training, guidance in 
performing an action. 
Stages-of-Change Model (Prochaska and Diclemente 1983): 
Pre-contemplation 
Unaware of problem hasn't thought 
about changes 
Increase awareness of the need for 
change, personalizes information on 
risks and benefits. 
Contemplation 
Thinking about change, in the near 
future. 
Motivate, encourage to make specific 
plans. 
Preparation Making a plan to change 
Assist in developing concrete action 
plans, setting gradual goals. 
Action 
Implementation of specific action 
plans 
Assist with feedback, problem solving, 
social support, reinforcement. 
Maintenance 
Continuation of desirable actions, or 
repeating periodic recommended 
step(s) 
Assist in coping, reminders, finding 
alternatives, avoiding slips/relapses (as 
applicable). 
Theory of Planned Behavior (Godin and Kok 1996) and Theory of Reasoned Action (Ajzen and 
Fishbein 1975): 
Behavioral intention 
Perceived likelihood of performing 
the behavior; prerequisite for action 
Define action; identify how much effort 
one is planning to exert to reach the 
goal. 
Attitude 
One's favorable or unfavorable 
evaluation of the behavior 
Identify outcomes of action. 
Behavioral belief 
Belief that behavioral performance is 
associated with certain attributes or 
outcomes 
Provide information about outcomes; 
clarify positive effects to be expected. 
Normative belief 
Subjective belief regarding approval 
or disapproval of the behavior 
Identify barriers and advantages of 
behavior. 
Subjective norm 
Influence of perceived social 
pressure; weighted by one's 
motivation to comply with perceived 
expectations 
Identify specific groups or individuals 
of influence; identify how much their 
approval or disapproval affects action. 
Perceived behavioral 
control (Theory of 
Reasoned Action only) 
One's perception of how easy or 
difficult it will be to act 
Incorporate information about likely 
results of action in advice. 
Social Cognitive Theory (Bandura 1977): 
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Concept Definition Application 
Reciprocal determinism 
Behavior changes result from 
interaction between individual and 
environment 
Work to change the environment. 
Behavioral capability 
Knowledge and skills to influence 
behavior 
Provide information and training about 
action. 
Expectations Beliefs about likely results of action 
Incorporate information about likely 
results of action into advice. 
Self-efficacy 
Confidence in ability to take action 
and persist in action 
Point out strengths; use persuasion and 
encouragement; approach behavior 
change in small steps. 
Observational learning Beliefs based on observing others 
Point out others' experience; identifies 
role models. 
Reinforcement 
Responses to a person's behavior that 
increase or decrease chances of 
recurrence 
Provide incentives, rewards, praise; 
encourage self-reward. 
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A3.3a Theoretical analysis of cognition 
(Model Proposed by Albus and Meystel (1996)) 
 
 
A3.3b Control Techniques 
(Control Theory 2016) 
 
Control Technique Description 
Adaptive control Uses on-line identification of the process parameters, or modification of 
controller gains, thereby obtaining strong robustness properties. Adaptive 
controls were applied for the first time in the aerospace industry in the 
1950s and have found particular success in that field. 
Hierarchical control 
system 
A type of control system in which a set of devices and governing software 
is arranged in a hierarchical tree. When the links in the tree are 
implemented by a computer network, then that hierarchical control system 
is also a form of networked control system 
Intelligent control Uses various AI computing approaches like neural networks, Bayesian 
probability, fuzzy logic, machine learning, evolutionary computation and 
genetic algorithms to control a dynamic system 
Optimal control A particular control technique in which the control signal optimizes a 
certain "cost index": for example, in the case of a satellite, the jet thrusts 
needed to bring it to the desired trajectory that consumes the least amount 
of fuel 
Robust control Deals explicitly with uncertainty in its approach to controller design. 
Controllers designed using robust control methods tend to be able to cope 
with small differences between the true system and the nominal model used 
for design. 
Stochastic control Deals with control design with uncertainty in the model. In typical 
stochastic control problems, it is assumed that there exist random noise and 
disturbances in the model and the controller, and the control design must 
take into account these random deviations 
Energy-shaping 
control 
View the plant and the controller as energy transformation devices. The 
control strategy is formulated regarding interconnection (in a power-
preserving manner) to achieve the desired behavior. 
Self-organized 
criticality control 
May be defined as attempts to interfere in the processes by which the self-
organized system dissipates energy. 
 
